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Abstract (250 word limit): 
Metabolic disorders are commonly associated with obesity, a condition 
where excess caloric intake leads to massive adipose tissue (AT) expansion and 
eventual dysfunction. When adipose tissue loses its ability to store excess 
energy properly, lipids accumulate in non-adipose tissues such as liver, and 
muscle. This ectopic lipid deposition is a significant risk factor in the development 
of a collection of disorders described as metabolic syndrome. While metabolic 
syndrome is typically linked with obesity, patients who have an inability to 
develop adipose tissue depots (lipodystrophy) develop similar clinical outcomes. 
There is evidence that aberrant mTORC1 signaling may occur in both settings, 
and may be a factor that contributes to adipose dysfunction.  
I find that adipocyte specific loss of Raptor, a key mTORC1 subunit, leads 
to progressive lipoatrophy, and associated metabolic dysfunction including AT 
inflammation, hepatosteatosis, and insulin resistance. Interestingly, inhibition of 
autophagy, a pathway upregulated during Raptor deletion, prevents lipoatrophy 
but does not protect from ectopic lipid deposition and AT inflammation. These 
results suggest that outputs of mTORC1 in adipocytes individually regulate 
adipocyte storage capacity, and AT health. Furthermore, ablation of the amino 
acid sensing RagGTPases, thought to be necessary for mTORC1 activity, does 
not phenocopy Raptor KO, suggesting RagGTPase independent functions of 
mTORC1 in adipocytes. RagA/B deletion, however, did consistently increase 
 
vi 
Ucp1 expression in WAT, indicating a possible noncanonical role of the Rags in 
regulating Ucp1. 
Overall, these studies advance our understanding of regulation of adipose 
tissue metabolism, and shed light on previously unstudied nutrient specific 
signaling pathways in adipocytes.  
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CHAPTER I: Introduction 
This chapter contains materials that are reprinted or have been adapted with permission 
from the Trends in Endocrinology and Metabolism article: 
 
Lee, P. L.1, Jung, S. M.1., Guertin, D. A. (2017). "The Complex Roles of Mechanistic 
Target of Rapamycin in Adipocytes and Beyond." Trends Endocrinol Metab 28(5): 319-
339. 
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Obesity in the USA 
In this day and age, obesity and its associated health consequences are 
generally well appreciated throughout society. From the 1980s into the early 
2000s, the USA experienced rapidly increasing rates of obesity throughout both 
the adult and youth population, quickly reaching epidemic levels. In recent years, 
extensive efforts have been made as a society to curb the obesity epidemic, and 
evidence indicates that the prevalence of obesity has been leveling off [1]. 
Despite this, obesity numbers in the USA remain staggering, with more than a 
third of adults classified as obese, as defined by a BMI of greater than 30 [2]. 
Comorbidities associated with obesity are vast and affect nearly all organs of the 
body. These include hypertension, diabetes, cardiovascular disease, stroke, 
gout, osteoarthritis, and more [3]. Given the serious health consequences 
associated with obesity, tremendous effort has been given in understanding the 
relationships between adipose tissue and overall human health. 
 
Adipose Tissue Mass vs Health 
While there is certainly a war on obesity in modern culture, it is important 
to note that the functionality of adipose tissue may be just as, or more, important 
to metabolic health than its gross mass. This idea was reported on as early as in 
the 1980s, with the identification of metabolically obese normal weight persons 
(MONW), whereby an individual may have generally a normal proportion of 
adipose tissue, however still suffer from metabolic consequences commonly 
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associated with obesity [4, 5]. Furthermore, there has also been interest 
generated in metabolically healthy obesity (MHO), in which a person’s BMI may 
be well within the obese range, however they do not suffer from metabolic 
consequences associated with obesity [6, 7, 8, 12]. More recently, it has been 
identified that the development of metabolic diseases and its relationship with 
adiposity may be significantly different among different cultures. In fact, 
recommendations have been made to adjust BMI standards for certain 
populations, for example, lowering the threshold of “overweight” for certain Asian 
populations [9]. To better understand the underlying reasons for these clinical 
outputs, we must investigate the biology of adipose tissue and adipocytes.  
 The ability to store excess energy in the form of lipids is a trait well 
conserved throughout evolution. From single-celled organisms storing lipids in 
the form of lipid droplets, to mammals with a complex heterogenous collection 
adipocytes, the storage of energy is critical for organism survival during times of 
nutrient starvation [10]. In addition to providing energy during times of need, it is 
thought that sequestration of lipids within adipocytes importantly protect other 
organs from “lipotoxicity” [11, 12]. This theory suggests that while other organs 
such as liver and muscle are capable themselves of transient energy stores, 
these tissues quickly become overwhelmed by excess lipids and will suffer 
metabolically when stressed [11, 12]. Indeed, high circulating free-fatty acid 
levels are tightly correlated with the development of insulin resistance and 
metabolic disease [13]. It has been shown that reducing circulating FFA, by 
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preventing the release of lipids from adipose tissue, may help improve insulin 
sensitivity and whole body metabolic function [14]. While metabolic dysfunction 
can still occur in cases of normal FFA levels, it is clear that proper adipose tissue 
function is critical in relieving peripheral organs of energy stress. This is well 
documented in the case of human lipodystrophy, a disease in which patients 
have a near complete inability to develop adipose stores, and thus suffer from 
severe insulin resistance and other metabolic diseases often seen in obesity [15]. 
In the case of obesity, MONW, and MHO persons, it is still unclear why, at 
different points, the adipocytes begin to lose their ability to safely and effectively 
store lipids.  
  
Adipose Tissue Depots 
In humans, adipocytes organize themselves into generally contained 
depots throughout the whole body, collectively making up the adipose organ. 
Historically, adipose tissue was generally thought to be a passive yet critical 
energy sink, storing lipids during times of nutrient excess, and providing energy 
sources during times of nutrient deprivation [10, 16]. On a more detailed level, 
adipose tissue is often classified as either white adipose tissue (WAT) or brown 
adipose tissue (BAT), although this is yet still an oversimplification as mounting 
evidence indicates different depots, and even individual adipocytes within depots, 
are heterogeneous with respect to development and function [17-19]. For 
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simplicity’s sake, however, I will touch on the significant differences between BAT 
and WAT. 
Both WAT and BAT depots are found in several anatomically defined 
locations in nearly all mammals. In mice, common depots used in the study of 
adipose tissue include interscapular BAT, anterior subcutaneous WAT, and 
perigonadal WAT [Figure 1.1A]. WAT persists in the body in distinct locations, 
and are commonly differentiated between visceral WAT (vWAT) and 
subcutaneous WAT (sWAT). Research has shown that vWAT, located internally 
and typically surrounding organs such as the gut and the heart, is highly 
associated with metabolic disorders [20]. sWAT, on the other hand, is found at 
the periphery, underneath the skin, and has been suggested that it may in fact 
provide metabolic benefits [15]. As a whole, WAT is unique in its incredible 
growth potential and energy storing capacity, which can be subsequently 
released when dietary nutrients are unavailable. WAT can expand tremendously 
during periods of chronic nutrient excess, which can be appreciated both under 
normal conditions, such as bears as they prepare for hibernation, or under 
diseased conditions such as human obesity.  
 
Brown Adipose Tissue 
While WAT is the most abundant type of adipose tissue present in 
humans, there is great interest in understanding the biology of BAT. Unlike white 
adipocytes, brown adipocytes are a highly active cell, consisting of many small 
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lipid droplets and packed with mitochondria (giving the “brown” appearance). 
Unlike WAT, BAT is actually a net energy consumer, and acts as a nutrient sink. 
The primary function of BAT is to generate heat (thermogenesis), which is an 
energy expending process mediated by uncoupling protein 1 (UCP1) [21, 22]. By 
consuming lipid species, the mitochondria in BAT generate tremendous amounts 
of heat while consuming intracellular energy stores. In humans, BAT is most 
abundant in infants, and is believed to play an important in role in maintaining 
body temperature at young ages. As humans age, they develop greater ability to 
generate heat through muscle contraction (shivering), and rely on manmade 
environments to help maintain temperature control, thus losing their dependence 
on BAT. Despite this, there has been intensified interest in understanding brown 
adipocyte biology in parallel with the idea that stimulating BAT activity 
therapeutically may be a way to combat obesity or hyperglycemia and 
hyperlipidemia [23]. Overall, it is clear that adipose tissue is an extremely 
complicated organ, and while its basic role is in storing lipids, there are a plethora 
of outputs and connections that cement it as a critical metabolic organ. Beyond 
controlling its overall growth in mass, regulating adipose tissue’s role as an 
endocrine organ, or its role in energy expenditure, may provide significant 
benefits in battling metabolic disorders. 
 
Beige Adipose Tissue 
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Interestingly, it has been shown that adipocytes that arise in traditionally 
WAT depots do have the ability to develop a brown-like characteristic, a process 
called “browning” or “beiging” [24]. Under certain stimulatory conditions, these 
white adipocytes can become energetically active with high numbers of 
mitochondria, and multiple small lipid droplets, becoming somewhat of an 
intermediary type of cell often referred to as a “beige” adipocyte [24]. These cells 
express high amounts of Ucp1, like brown adipocytes, and behave similarly in 
that they will consume nutrients to expend energy in the form of heat. The most 
common way to stimulate this “beiging” process is cold exposure. In mice, 
housing animals in cold conditions (most commonly around 4°C-6°C), induces a 
thermal stress that significantly activates and produces many beige cells within 
WAT depots [25]. More specifically, white adipocytes found in subcutaneous 
depots appear to have a greater propensity for beiging, while vWAT adipocytes 
undergo minimal transitions even during times of chronic cold stimulation [26]. 
This activity and ability to beige in scWAT is one mechanism proposed to explain 
the observations that scWAT may be a “healthier” type of WAT depot when 
compared to vWAT. On the other-side of the spectrum, when stimulatory factors 
are minimalized, such as at warm, “thermoneutral” conditions, brown adipocytes 
can take on a white-like morphology in greatly expanding the size of their lipid 
droplets [27]. It is clear that adipose tissue and adipocytes are dynamic in nature, 
and feature the ability to regulate their metabolic programs in response to 
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environmental cues and stresses. Examples of these dynamics shifts are shown 
in Figure 1.1.  
 
Figure 1.1: Diagram representing anatomic location of commonly studied WAT 
and BAT depots in mice. Histological images show the dynamic response of 
adipose tissue morphology to environmental cues.  
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Metabolic Signaling  
As appreciation for the diversity of adipose tissue grows, so does the 
interest in understanding how nutrients and signaling molecules regulate 
adipocyte dynamics. The ability of biological systems to sense and respond 
appropriately to nutrient availability is crucial for survival.  Consequently, animals 
are layered with multiple nutrient sensing mechanisms at the cell, organ, and 
organism level. At the cellular level, nutrient signaling biochemistry is best 
understood in cells where mTOR is the marquee intracellular kinase linking 
nutrient availability with metabolic control. In many studies utilizing different 
model cell lines, it’s been shown that mTOR deregulation is a hallmark of 
diabetes and cancer [28]. The functions of mTOR are split between two multi-
subunit complexes, called mTOR complex 1 (mTORC1) and mTORC2 [Figure 
1.2A].  The best-understood complex is mTORC1, which is a well-known engine 
of anabolic metabolism that functions downstream of an ancient amino acid 
sensing network superimposed by growth factor signaling in higher eukaryotes 
[Figure 1.2C] [28, 29].  Its sibling, mTORC2 is less well-defined biochemically, 
but is emerging as a central regulator of glucose and lipid metabolism. The 
intracellular mechanics of mTOR signaling are being extensively defined in cell 
culture systems [30-33]; less understood are the in vivo organ-specific functions 
of mTOR and its role in organ-to-organ communication networks.  Interest in 
mTOR is also driven by the fact that mTOR inhibitors are highly desirable 
pharmacological agents, particularly in oncology and immunology. Thus, 
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understanding how mTOR’s diverse cellular functions are integrated at the organ 
and organism level is key challenge area.  
 
mTOR Complex 1 
The complexity of mTORC1 signaling has been extensively described [28, 
34].  To summarize, mTORC1 is mainly activated by combined inputs from amino 
acid sensing pathways and growth factor signaling such as the insulin and insulin 
like growth factor 1 (IGF1) pathways [Figure 1.2C].  Many additional inputs 
ranging from the energy sensing AMP-activated protein kinase (AMPK) signaling 
pathway to cellular stresses like hypoxia fine-tune mTORC1 activity essentially to 
optimize (or restrict) anabolic growth in coordination with the cell's nutrient and 
energy availability. Recent breakthroughs in understanding the amino acid 
sensing mTORC1 inputs reveal that cytoplasmic levels of leucine and arginine 
are directly sensed by the Sestrins and Castor proteins respectively, which 
promote the GTP loading of a small GTPase called RagA/B. The mechanistic link 
between Senstrins/Castor and RagA/B activation is poorly understood but 
involves two large protein complexes, the Gator2 (Mios, Seh1L, WDR24, 
WDR59, Sec13) and Gator1 (DEPDC5, Nprl2, Nprl3) complexes. Glutaminolysis, 
the breakdown of glutamine to α-ketoglutarate, might also help facilitate leucine-
dependent RagB loading [35]. RagA/B GTP loading promotes mTORC1 
localization to lysosomes where it encounters its activator, the Rheb-GTPase. By 
mechanisms less clear, amino acids can also signal to mTORC1 from within the 
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lysosomes through Slc38A9 and the v-ATPase [36, 37]. Elucidating the amino 
acid inputs to mTORC1 is an ongoing and exciting area of research in part 
because it may be possible to manipulate mTORC1 activity pharmacologically 
with amino acid analogs.     
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Figure 1.2: A, B) Individual components of mTOR Complex 1 C) Identified 
upstream and downstream effectors of mTORC1 
 
At the lysosome, Rheb directly activates mTORC1 [38-40]. Rheb activity is 
controlled by the TSC complex (TSC1, TSC2, TBC1D7), a GAP that is inhibited 
by insulin/AKT signaling forming the main convergence point between growth 
factor and amino acid regulation of mTORC1 [41, 42]. There are several known 
mTORC1 substrates that collectively promote anabolic growth [Table 1] including 
the classic mTORC1 effectors S6K1 and 4E-BP1, which regulate protein 
synthesis [28] Other effectors include Ulk1, a kinase involved in autophagy [43], 
and TFEB, a transcription factor protein also important in autophagy through its 
role in lysosomal biogenesis [44]. Additional evidence exists for mTORC1 being 
involved in lipid metabolism through phosphorylation of Lipin1, a phosphatidic 
acid phosphatase [45, 46], and Grb10, a  negative regulator of insulin/IGF 
receptor signaling that may play a role in regulating lipolysis and thermogenesis 
in adipose tissue [47, 48].  Some substrates, such as S6K1 and Grb10 can also 
inhibit insulin signaling forming powerful negative feedback loops allowing for 
tight control of insulin/IGF signaling [49, 50]. 
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Figure 1.3: Common downstream targets of mTORC1 activity 
 
mTOR in the Clinic 
Pharmacological inhibitors of mTOR are highly desired agents in oncology 
and transplant medicine, thus understanding the mechanistic basis of their side 
effects could improve efficacy.  Rapamycin (Sirolimus, INN/USAN) is a widely 
used immunosuppressant particularly in kidney transplantation.  Mechanistically, 
rapamycin is an immunophillin that functions as an mTOR inhibitor only when 
bound to FKBP12.   Patients on rapamycin often development new onset 
diabetes after transplantation (NODAT), which can increase post-transplant 
morbidity and mortality [3, 51].  The exact mechanisms by which NODAT 
develops is not understood [51-53].  Could rapamycin cause insulin resistance in 
part by inhibiting mTOR in adipose tissue?  Rapamycin acutely inhibits mTORC1; 
however, prolonged rapamycin exposure as discussed earlier additionally inhibits 
mTORC2 [54, 55] by preventing new Rictor-mTOR interactions [54].  Moreover, 
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very high doses of rapamycin are also capable of binding the FRB domain 
independently of FKB12 and inhibiting mTORC2 [56].  As genetic studies indicate 
that selectively losing either mTORC1 or mTORC2 in adipose tissue impairs 
insulin sensitivity, it is possible that rapamycin can compromise metabolic 
homeostasis by targeting either complex in the adipose tissue. Rapamycin’s 
ability to inhibit mTORC2 in the liver is likely due to its undesirable side effects in 
this tissue [55].  
Given that many cancers have elevated mTOR signaling, there is also 
great interest in mTOR inhibitors for use in oncology [57-59].  Rapamycin and its 
analogs have been developed for this purpose, but in many cases, were met with 
limited success in part due to incomplete mTOR inhibition and loss of negative 
feedback inhibition of AKT and cell survival.  More recently, major investments 
have been made towards developing mTOR catalytic inhibitors that target the 
kinase domain. Several of these compounds, often referred to as 2nd generation 
mTOR inhibitors, are currently being tested in early clinical trials [Table 2]. While 
these 2nd generation inhibitors do a better job of complete mTOR inhibition, 
feedback pathways, drug resistance, and toxicity remain challenges [57]. More 
recently a novel “3rd generation” mTOR inhibitor (RapaLink) was created by 
crosslinking rapamycin with an mTOR kinase inhibitor, allowing for the drug to 
bind at both the FRB and the kinase domain. In preclinical studies, RapaLink has 
shown promise in overcoming some types of mutation mediated drug resistance 
[Table 2] [60]. Despite these significant advances, major hurdles still remain in 
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understanding and overcoming mTOR inhibition related toxicity in normal tissues. 
Continued elucidation of mTORC1 and mTORC2’s mechanisms of action in 
metabolic tissues like adipose tissue, liver, and skeletal muscle is essential to 
understanding how to cope with the side effects of mTOR-targeted therapies.        
 
Figure 1.4: Progress of mTOR targeting therapies in clinical development 
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Adipose Tissue mTORC1 
While mTORC1 is a critical regulator of cell growth and anabolic 
processes in cells, its tissue-specific roles in adipose tissue have not been 
extensively defined.  Because mTOR is the catalytic subunit of both mTORC1 
and mTORC2, tissue specific genetic analysis of each complex relies upon the 
selective deletion of essential regulatory subunits using Cre-Lox technology.  For 
mTORC1, this is achieved by deleting Raptor [Figure 1.2A].  A previous genetic 
study of mTORC1 in adipose tissue utilized the aP2-Cre driver to delete Raptor 
[61]. In summary, this study concluded that deletion of Raptor led to mice that 
had increased energy expenditure and were resistant to high-fat diet induced 
obesity. This study suggested that mTORC1 inhibition in adipose tissue may 
overall provide a metabolic benefit. Since that study, however, aP2-Cre has 
fallen out of favor due to its inefficient targeting of adipocytes and “off-target” 
expression e.g. in endothelial and brain cells [62-64]. It is generally accepted now 
that Adiponectin-Cre is more specific and efficient at targeting mature adipocytes 
(though all Cre drivers should be used with caution). Adiponectin-Cre also targets 
all mature adipocytes, including both brown and white, therefore it cannot be 
used to conclusively distinguish the depot independent functions of a specific 
target. While those results using aP2-Cre were provocative, it will be important to 
understand a more specific role of mTORC1 in adipocytes utilizing newer genetic 
tools.  
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mTORC1 Effectors in Adipose Tissue 
Growth factor signaling regulates mTORC1 activity through a pathway 
different from amino acids, and proteomic studies suggest that the global 
phosphorylation response to insulin is largely mTOR dependent [47]. It was 
reported recently that mice lacking the insulin receptor (IR) in mature adipocytes 
(IRAdipoq-Cre mice) suffer from lipodystrophy [65], while a fat-specific IR/IGFR 
double KO model results in a complete loss of adipose tissue and more severe 
metabolic disease [65]. However, knocking out all adipocyte AKT activity by 
simultaneously deleting AKT1 and AKT2 (i.e. AKT1;AKT2Adipoq-Cre double KO 
mice) also causes a severe lipodystrophy [66] indicating other insulin/AKT 
effectors in addition to mTORC1 are also critical for adipose tissue maintenance.  
Alternatively, losing mTORC1-dependent feedback inhibition of AKT might 
preserve some adipose tissue in the absence of Raptor.  Consistent with the 
latter possibility, overexpressing the mTORC1/2 complex subunit DEPTOR 
promotes adipogenesis by dampening mTORC1 activity, which reduces 
mTORC1-mediated feedback inhibition of insulin signaling, and promotes AKT-
PPARy activity [67]. A similar effect was observed in cell culture where a 
conditional knockdown approach in 3T3-L1 cells that partially inhibits mTOR 
activity promotes adipogenesis by increasing AKT signaling [68].  One prediction 
of these observations is that inhibiting both mTORC1 and mTORC2 (because it 
phosphorylates AKT) might result in more severe loss of adipose tissue.  
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However, Adipo-Cre mTOR L/L mice are phenotypically similar to Adipo-Cre 
Raptor L/L mice [69] suggesting that mTORC2-independent AKT signaling may 
promote the maintenance of some, albeit smaller, fat depots in the Adipo-Cre 
Raptor L/L mice. 
 
Adipose mTORC1 and Lipodystrophy 
At the start of this project, despite many studies in focusing on adipose 
tissue metabolism, the specific role of mTORC1 activity in mature adipocytes 
was not completely understood. Given the many downstream mTORC1 targets, 
there are multiple possibilities that are not necessarily mutually exclusive. 
Indeed, many mTORC1 effectors have reported roles in adipocytes [70, 71].   
Because mTORC1 suppresses autophagy, one possibility is that Raptor loss in 
fat may lead to excessive degradation and loss of adipocytes.  In fact, from a 
human perspective, some types of congenital generalized lipodystrophy (CGL), 
may occur in part due to mutations that affect autophagic lipid degradation. For 
example, CGL has been linked to mutations in 1-Acylglycerol-3-Phosphate O-
Acyltransferase 2 (AGPAT2) and SEIPIN, also known as Bernardinelli-Seip 
congenital lipodystrophy type 2 protein (BSCL2), both endoplasmic reticulum 
membrane proteins involved lipid biosynthesis that may also play a role in 
lipophagy [72, 73].  Additionally, a recent study found that deleting AGPAT2 in 
adipose tissue increases autophagic structures.  Interestingly, other recent work 
finds that SEIPIN can interact directly with both AGPAT2 and the mTORC1 
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substrate Lipin1 in a complex [74].  This potentially directly links human 
lipodystrophies to the mTORC1 signaling pathway as it has been shown that 
mTORC1 may regulate lipin1 localization and activity [45, 46], and mice carrying 
a mutation in the lipin1 gene exhibit features similar to human lipodystrophy and 
fat-specific Raptor loss [75].  
Given the above information, I am presented with conflicting ideas, one 
based on the results of an aP2-Cre driven deletion of Raptor which would 
suggest that mice may benefit metabolically from mTORC1 inhibition, while 
several others studies suggest that mTORC1-associated proteins and signaling 
pathways might be crucial for adipose tissue development and maintenance. 
Given our knowledge of downfalls of the aP2-Cre system and understanding of 
the role of mTORC1 in anabolic pathways, I believe that inhibition of Raptor in 
mature adipocytes will lead to metabolic dysfunction in an animal model. This 
sets the groundwork for a major aim of this project.  
mTORC1 in BAT 
Previously it was discussed that BAT has emerged as a promising type of 
adipocyte that may play a role in combating metabolic dysfunction. Recent 
studies have also begun looking at the role of mTORC1 in BAT.  Using Adipo-
Cre Raptor L/L mice, one study looked carefully at how losing mTORC1 in all 
mature adipocytes affects BAT adaptation to cold [76].  In wild type mice, 
prolonged cold challenge significantly increases mTORC1 activity in BAT through 
sympathetic signaling and this correlates with increased BAT mass, 
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mitochondrial biogenesis, and oxidative metabolism.  Without Raptor, BAT 
cannot expand or metabolically adapt to cold. Deleting Raptor only in BAT with 
Ucp1-Cre (RaptorUcp1-Cre) also reduces BAT mass and lipid content [77], arguing 
that this is likely a tissue-autonomous effect.  Further studies using BAT specific 
Cre drivers are needed to confirm the BAT-specific mTORC1 functions.       
mTORC1 in Browning/Beiging  
When mice are exposed to severe cold for prolonged periods of time, or 
treated with beta-adrenergic agonists, some depots can metabolically reprogram 
to become characteristically more similar to brown adipocytes, for example they 
induce UCP1 expression [78, 79]. This is often referred to as the browning of 
WAT and may have therapeutic potential in humans by functioning as a glucose 
and energy sink in the setting of diabetes/obesity [80].  In two independent 
studies, it was recently found that the mTOR inhibitor rapamycin blocks WAT 
browning [81, 82].  Interpreting the effect of rapamycin is complex because it is 
systemically delivered, it only partially inhibits mTORC1 [83, 84] and it can also 
inhibit mTORC2 following prolonged exposure [54].  To address the specificity of 
rapamycin’s effect in vivo, both studies used Adipo-Cre Raptor L/L mice to show 
that Ucp1 cannot be induced by cold [81, 82] or beta-adrenergic agonists [81, 82] 
without functional mTORC1 in WAT.  In agreement, another recent study finds 
that activating mTORC1 in WAT by deleting its negative regulator TSC1 (Adipo-
Cre TSC1 L/L  mice) elevates Ucp1, PGC-1α, and PPARα levels [85]. In cultured 
adipocytes, βAR agonists were also shown to stimulate S6K but not AKT 
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phosphorylation, suggesting a link between mTORC1 and protein kinase A (PKA) 
signaling [82].  Indeed, a PKA inhibitor blocked this effect and this was attributed 
to direct phosphorylation of mTORC1 (on both mTOR and Raptor) by PKA 
[Figure 1C].  Thus, in addition to its regulation by insulin, a well-known antagonist 
of PKA signaling, mTORC1 also responds to catecholamines in adipocytes.  
Concurrently, other studies have shown that adrenergic stimulation may also 
stimulate mTORC2 and AKT signaling in certain settings suggesting that 
catecholamine-stimulated mTOR activity may be complex [76, 86].   
Summary 
While there are many paths to pursue in understanding nutrient signaling, 
adipose tissue metabolism, and whole body metabolic health, I set out to develop 
a better understanding of the role of mTORC1 signaling in adipose tissue 
metabolism. Specifically, I want to understand how mTORC1 in mature 
adipocytes contributes to the ability of adipose tissue to regulate whole body 
metabolism. While previous studies have suggested that adipose ablation of 
mTORC1 activity using the aP2-Cre results in metabolically superior mice, there 
are substantial data that argue downstream targets of the mTORC1 pathway are 
crucial for adipose tissue function maintenance [61, 69, 87]. To test the role of 
mTORC1 in mature adipose tissue, I generated mice that are genetically ablated 
for Raptor, specifically in adipocytes using the Adiponectin-Cre. While it was 
possible this KO may end up phenocopying the aP2-Cre mice, I found that these 
mice were in fact extremely different than the previously understood model [77]. 
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Adipose tissue ablation of mTORC1, using Adiponectin-Cre, resulted in 
metabolically unfit mice who suffered from severe lipodystrophy. Using this Cre 
with greater specificity and efficacy for mature adipocytes, I found that the loss of 
mTORC1 signaling resulted in mice that not only were unable to expand their 
adipose tissue, but they also suffered from a progressive loss of adipose stores 
as they aged. In addition, they suffered from metabolic disfunction such as 
hepatic steatosis, insulin resistance, and hepatic tumor growth [77].  
 From these results, I next wanted to dissect the numerous downstream 
changes in these Raptor KO mice to identify key players that contribute to 
lipodystrophy and metabolic dysfunction. Of interest was understanding time-
dependent consequences of mTORC1 ablation. With the previous tool of 
Adiponectin-Cre, Raptor is consequently deleted immediately after an adipocyte 
differentiates, resulting in mTORC1 inhibition even before birth. To better mimic 
adipose tissue dysfunction in the setting of human disease, I generated tools to 
allow me to genetically ablate mTORC1 signaling in adult mice at any time point 
desired using both a tamoxifen inducible and a doxycycline inducible Cre system 
linked with adiponectin-drivers. In summary, I find that aberrant signaling 
responses occur in an acute setting, however the development of lipodystrophy 
and metabolic disease do not occur until many weeks after these signaling 
changes. I observed that the progression of metabolic dysfunction closely 
associated with the appearance of adipose tissue loss, and adipocyte shrinkage 
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and death. This led me to believe that the onset of lipodystrophy in adipocyte 
Raptor loss may be due to a chronic and progressive loss of adipocytes.  
I hypothesized that by activating the autophagic pathway, through loss of 
mTORC1 inhibition of ULK1, the adipocytes of these animals experienced faster 
rates of death, leading to loss of adipose tissue mass. I also hypothesized that 
the development of metabolic disorders such as hepatic steatosis and insulin 
resistance were dependent on the loss of adipose tissue mass and adipocyte 
survival capacity, and that rescuing the lipoatrophy defect would also rescue the 
metabolic dysfunction. To test this, I generated Adiponectin-Cre driven double 
KO mice of Raptor and ATG7, a key protein required for autophagy. I found that 
these mice do in fact recover their adipose tissue mass, suggesting that the 
progress lipoatrophy seen in adipose Raptor KO mice is dependent on 
mTORC1’s inhibition of autophagy. Surprisingly, however, these mice did not 
seem to recover metabolically, and continued to suffer from adipose tissue 
inflammation, and hepatic steatosis. These results suggest that recovery of 
adipose tissue mass alone is insufficient to restore metabolic homeostasis, and 
that additional mTORC1 dependent pathways in adipocytes may be critical in 
regulating whole body metabolism.  
 Lastly, discussed earlier was the current understanding of mTORC1 
signaling and its dependence on the amino acid sensing pathway. While most of 
the biochemistry has been worked out in in vitro cancer cell models, I wanted to 
explore the role of this pathway in an animal model, specifically relating to 
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adipose tissue. Based on aforementioned data, I believed that the amino acid 
sensing RagGTPases would be critical in adipocytes to maintain both mTORC1 
activity, and adipose tissue health. I hypothesized that ablation of the 
RagGTPases in mature adipocytes would phenocopy mTORC1 ablation, 
indicating the necessity of proper amino acid sensing and signaling to maintain 
whole body metabolism. To test this, I generated adipose tissue RagA and RagB 
double KO mice driven by Adiponectin-Cre. Surprisingly these mice are generally 
phenotypically normal, absent lipodystrophy or metabolic dysfunction. They also 
appear to have largely intact downstream mTORC1 signaling suggesting that, in 
mature adipocytes, the RagGTPases may be dispensable for mTORC1 
signaling.  
 Overall, I have identified mature adipocyte mTORC1 as a key regulator for 
both adipocyte, and whole-body metabolism. It appears that mTORC1’s inhibition 
of autophagy is necessary for the maintenance and growth of adipose tissue, and 
that loss of mTORC1 results in severe lipoatrophy, along with development of 
metabolic diseases such as hepatosteatosis, and insulin resistance. Rescue of 
adipose tissue mass via inhibition of autophagy, however, is also insufficient to 
restore metabolic homeostasis, suggesting that other downstream mTORC1 
pathways within adipocytes are crucial for energy regulation throughout other 
tissues in the body. Lastly, it appears that while adipocytes are amino acid 
sensitive in culture, the specific RagGTPases may be dispensable for mTORC1 
signaling in adipose tissue. With this knowledge, there are a plethora of future 
 
25 
projects worth pursing related to nutrient sensing signaling, adipose tissue, 
metabolism, and cancer. 
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CHAPTER II: Raptor/mTORC1 Loss in Adipocytes Causes 
Progressive Lipodystrophy and Fatty Liver Disease 
 
This chapter contains materials that are reprinted or have been adapted with permission 
from the Molecular Metabolism article: 
 
Lee, P. L., Tang Y., Li H., Guertin D.A., (2016). "Raptor/mTORC1 loss in adipocytes 
causes progressive lipodystrophy and fatty liver disease." Mol Metab 5(6): 422-432. 
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Abstract:  
Objective: Normal adipose tissue growth and function is critical to maintaining 
metabolic homeostasis and its excess (e.g. obesity) or absence (e.g. 
lipodystrophy) is associated with severe metabolic disease. The goal of this study 
was to understand the mechanisms maintaining healthy adipose tissue growth 
and function. 
Methods: Adipose tissue senses and responds to systemic changes in growth 
factor and nutrient availability; in cells mTORC1 regulates metabolism in 
response to growth factors and nutrients. Thus, mTORC1 is poised to be a 
critical intracellular regulator of adipocyte metabolism. Here, I investigate the role 
of mTORC1 in mature adipocytes by generating and characterizing mice in which 
the Adiponectin-Cre driver is used to delete floxed alleles of Raptor, which 
encodes an essential regulatory subunit of mTORC1.  
Results: Raptor Adipoq-cre mice have normal white adipose tissue (WAT) mass 
for the first few weeks of life, but soon thereafter develop lipodystrophy 
associated with hepatomegaly, hepatic steatosis, and insulin intolerance. Raptor 
Adipoq-cre mice are also resistant to becoming obese when consuming a high 
fat diet (HFD). Resistance to obesity does not appear to be due to increased 
energy expenditure, but rather from failed adipose tissue expansion resulting in 
severe hepatomegaly associated with hyperphagia and defective dietary lipid 
absorption. Deleting Raptor in WAT also decreases C/EBPa expression and the 
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expression of its downstream target adiponectin, providing one possible 
mechanism of mTORC1 function in WAT.  
Conclusions: mTORC1 activity in mature adipocytes is essential for maintaining 
normal adipose tissue growth and its selective loss in mature adipocytes leads to 
a progressive lipodystrophy disorder and systemic metabolic disease that shares 
many of the hallmarks of human congenital generalized lipodystrophy.  
 
1. INTRODUCTION  
White adipose tissue (WAT) functions both as the body’s major energy 
storage site, and as a critical endocrine tissue, and interest in understanding its 
biology has intensified with the obesity epidemic. Obesity (defined as a BMI > 30) 
results from energy imbalance and can lead to ectopic lipid deposition in non-
adipose tissues (e.g. the liver), type 2 diabetes, cardiovascular disease, and 
some cancers. Obesity now affects more than 1 in 3 adults in the United States, 
and between 8% and 25% of adults in countries of the European Union, making 
this a major international clinical problem of this era. Lack of adipose tissue or 
lipodystrophy also associates with severe metabolic complications. For example, 
patients suffering from congenital generalized lipodystrophy (or Berardinelli-Seip 
Syndrome) also develop insulin resistance, hypertriglyceridemia, and fatty liver 
disease, which can lead to hepatomegaly and liver failure. Thus, normal adipose 
tissue growth and function is critical to maintaining metabolic homeostasis and 
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understanding the mechanisms that promote healthy fat has broad clinical 
implications.  
The mechanistic target of rapamycin complex 1 (mTORC1) integrates 
multiple upstream signals from nutrient availability to promote anabolic 
metabolism. For example, mTORC1 detects intracellular amino acid availability 
through multiple sensors that converge upon the Rag GTPases to control 
mTORC1 subcellular localization, and circulating glucose levels through the 
insulin-signaling pathway, which promotes mTORC1 activity through the 
TSC/Rheb pathway [28] [36] [30] Thus, mTORC1 is poised to be a critical 
regulator of adipocyte function. To test this, I conditionally deleted the essential 
mTORC1 regulatory subunit Raptor in mature adipocytes with Adiponectin-Cre, 
which is reported to have greater efficiency and specificity for mature adipocytes 
than aP2-Cre [62, 88-91]. I find that Raptor Adipoq-Cre mice have normal WAT 
mass for the first few weeks of life, but progressively develop a lipodystrophy 
disorder resembling human congenital generalized lipodystrophy including insulin 
intolerance and hepatic steatosis. These and several additional characteristics of 
the Raptor Adipoq-Cre mice differ significantly from those of mice in which 
Raptor was deleted with aP2-Cre [61]. Our results provide a new framework for 
understanding how mTORC1 signaling helps maintain healthy adipose tissue 
and could provide insight into human lipodystrophy disorders.  
 
2. MATERIALS & METHODS  
 
30 
2.1. Mice  
Raptor floxed mice are described in [46] and were backcrossed 10 generations to 
C57BL/6J from Jackson Laboratory, and crossed to C57BL/6J background mice 
expressing the Adiponectin-Cre driver or the Ucp1-Cre driver (generous gifts of 
Evan Rosen). Floxed Cre-negative mice were used as controls. Mice were kept 
on a daily 12 h light/dark cycle and fed a normal chow diet (Prolab Isopro RMH 
3000) from Lab Diet ad libitum at 22° C. Male mice were used for experimental 
studies. All animal experiments were approved by the University of 
Massachusetts Medical School animal care and use committee.  
2.2. Antibodies and reagents  
PPARg antibody was from Santa Cruz (sc-7196). UCP1 antibody is from AbCam 
(ab-10983). All other antibodies were purchased from Cell Signaling 
Technologies: ACC (3676), ACLY (4332), AKT (9727), P-AKT- S473 (4058), 
ATGL (2439), FASN (3180), HSL (4107), P-HSL-S660 (4126), ULK1 (8054), P-
ULK1-S757 (6888), 4EBP1 (9644), P-4EBP1- S65 (9456), P-4EBP1-T37/46. All 
other reagents were from Sigma Aldrich.  
2.3. Diet & metabolic studies  
At 12 weeks of age, male mice were placed on a 60% high fat diet (HFD) 
(D12492 Harlan Laboratories) for 8 weeks. Body weight was recorded weekly. 
The analysis of blood metabolites was performed by the Joslin Diabetes Center 
and MMPC at the University of Cincinnati. For glucose tolerance tests (GTT) 
mice were fasted overnight (16 h) and then administered 2 g/kg of body weight of 
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glucose or sodium pyruvate by intraperitoneal (i.p.) injection. For insulin tolerance 
tests (ITT), mice were fasted for 6 h before i.p. administration of 0.75 unit/kg of 
body weight of insulin. Blood glucose concentrations from tail vein collection 
were measured before and after the injection at indicated time points. A GE100 
Blood Glucose monitor system was used. 
2.4. Tissue harvest and histology  
Adipose tissue depots were carefully dissected to avoid contamination from 
surrounding tissue. Samples for RNA or protein were snap frozen in liquid 
nitrogen and stored at 80° C until analysis. For histology, tissue pieces were fixed 
in 10% formalin. Embedding, sectioning, and Hematoxylin & Eosin (HE) staining 
was done by the UMass Medical School Morphology Core. For Oil Red O 
staining, liver samples were embedded in Optimal Cutting Temperature 
compound before sectioning and staining. For cell size measurements a 
minimum of 10 images were taken used per mouse (n = 3 wild type and 3 
conditional knockouts). Image J was used to measure cell size and the 
distribution of cell size as percentage of total counted cells was analyzed.  
2.5. Western blots  
Tissue samples or cells were lysed in a buffer containing 50 mM Hepes, pH 7.4, 
40 mM NaCl, 2 mM EDTA, 1.5 mM NaVO4, 50 mM NaF, 10 mM sodium 
pyrophosphate, 10 mM sodium β-glycerophosphate and 1% Triton X-100. 
Tissues were homogenized using a TissueLyser (Qiagen) in the same lysis 
buffer supplemented with 0.1% SDS, 1% sodium deoxycholate. Equal amounts 
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of total protein were loaded into acrylamide/bis-acrylamide gels and transferred 
to PVDF membranes for detection with the indicated antibodies. Membranes 
were incubated with primary antibodies in 5% milk/PBST or 5% BSA/PBST 
overnight. Membranes were then incubated for 1hr with HRP-conjugated 
secondary antibodies. Western blots were developed by enhanced 
chemiluminescence (PerkinElmer) and detected by X-ray films. 
2.6. Lipolysis  
Excised pgWAT tissue was incubated in 12 well cell culture dishes in DMEM with 
or without isoproterenol at 10 nM for 4 h, respectively, before collecting medium 
to measure glycerol concentration using a commercial kit (Sigma). The glycerol 
level was normalized with mass of the excised tissue.  
2.7. Fecal lipids extraction  
Mice were housed individually for 48 h and 1 g of dried feces was collected from 
each mouse. Feces were powderized using a tissue grinder, and rehydrated in 5 
ml of normal saline. A 2:1 chloroform:methanol solution was used to extract lipids 
from the suspension. To extract lipids, suspension was centrifuged and liquid 
phase was extract into a pre-weighed glass tube. Leaving the glass tubes in a 
fume hood, liquid was let to evaporate, leaving dry lipid content. Glass tubes 
were reweighed to determined total weight of lipids. A detailed protocol can be 
found at https://bio-protocol.org/e1375.  
2.8. Body composition and metabolic cages  
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Mice were placed into metabolic cages for 3 days at 25 days into their HFD 
feeding. Lean mass and whole-body fat mass were measured noninvasively 
using 1H-MRS (Echo Medical Systems, Houston TX), and a 3-day measurement 
of physical activity, energy expenditure, respiratory exchange ratio, and food 
intake were conducted using metabolic cages (TSE Systems, Bad Homburg, 
Germany) by the UMass Mouse Metabolic Phenotyping Center. Thereafter, mice 
were kept on HFD in normal housing until dissection.  
2.9. Gene expression analysis  
Cells or tissues were lysed with Qiazol (Invitrogen) and total RNA was isolated 
with the RNeasy kit (Invitrogen). Equal amounts of RNA were retro-transcribed to 
cDNA using a High capacity cDNA reverse transcription kit (#4368813, Applied 
Biosystems). Quantitative RT- PCR was performed in 10 mL reactions using a 
StepOnePlus real- time PCR machine from Applied Biosystems using SYBR 
Green PCR master mix (#4309156, Applied Biosystems) according to 
manufacturer instructions. Relative mRNA expression was determined by the 
ΔCt method, and Tbp (TATA sequence binding protein) expression was used as 
a normalization gene in all conventional RT- PCR experiments. Mouse primers 
used: 
Gene   Forward primer (5'-3')    Reverse primer (5'-3')  
Tbp   GAAGCTGCGGTACAATTCCAG  CCCCTTGTACCCTTCACCAAT  
Sreb1c   AAGCAAATCACTGAAGGACCTGG  AAAGACAAGCTACTCTGGGAG  
Chrebpα  CGACACTCACCCACCTCTTC   TTGTTCAGCCGGATCTTGTC  
Chrebpβ  TCTGCAGATCGCGTGGAG   CTTGTCCCGGCATAGCAAC  
Acly   CTCACACGGAAGCTCCATAA   ACGCCCTCATAGACACCATC  
Acaca   GGAGATGTACGCTGACCGAGAA  ACCCGACGCATGGTTTTCA 
Fasn   GCTGCGGAAACTTCAGGAAAT  AGAGACGTGTCACTCCTGGACTT  
Scd1   CCCTGCGGATCTTCCTTATC   TGTGTTTCTGAGAACTTGTGGTG  
Ppary1   TGAAAGAAGCGGTGAACCACTG  TGGCATCTCGTGTCAACCATG 
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Ppary2   TGGCATCTCTGTGTCAACCATG  GCATGGTGCCTTCGCTGA 
Ucp1   CTGCCAGGACAGTACCCAAG  TCAGCTGTTCAAAGCACACA  
Ppargc1a CCCTGCCATTGTTAAGACC   TGCTGCTGTTCCTGTTTTC  
Lpl   GGCCAGATTCATCAACTGGAT  GCTCCAAGGCTGTACCCTAAG 
Prdm16  CACCTCTGTATCCGTCAGCA   CACCTCTGTATCCGTCAGCA  
Pgc1a  CCCTGCCATTGTTAAGACC  TGCTGCTGTTCCTGTTTTC 
Ucp1  CTGCCAGGACAGTACCCAAG  CTGCCAGGACAGTACCCAAG 
C/ebpα   CAAGCCCAGCAACGAGTACCG  GTCACTGGTCAACTCCAGCAC  
C/ebpβ  TCGGGACTTGATGCAATCC   AAACATCAACAACCCCGC  
C/ebpδ   GCTTTGTGGTTGCTGTTGAA   ATCGACTTCAGCGCCTACA  
aP2   GATGCCTTTGTGGGAACCT   CTGTCGTCTGCGGTGATTT 
Cidea   ATCACAACTGGCCTGGTTACG  TACTACCCGGTGTCCATTTCT  
Dpt   CTGCCGCTATAGCAAGAGGT  TGGCTTGGGTACTCTGTTGTC  
Srebf2   GGATCCTCCCAAAGAAGGAG  TTCCTCAGAACGCCAGACTT  
Tfam   GTCCATAGGCACCGTATTGC   CCCATGCTGGAAAAACACTT 
Cpt1b   GGGCACCTCTGGGAGTTTGT  TTGGCTCACCCACACAGTGT  
 
2.10. Statistics  
Unless otherwise stated, values given are mean  SEM. Two-way ANOVA was 
performed where indicated. For most experiments, unpaired two-tailed Student’s 
t test was used to determine statistical significance among two groups (*p < 0.05; 
**p < 0.01; ***p < 0.001).  
 
3. RESULTS AND DISCUSSION: 
3.1. Adipocyte Raptor KO mice have normal WAT mass early in life. 
To investigate the role of mTORC1 in adipocytes, I generated Adiponectin-
Cre;Raptorfl/fl mice (herein Raptor Adipoq-cre mice). Raptor Adipoq-cre mice are 
born at the expected Mendelian ratio and are grossly indistinguishable from their 
littermates at birth. At post-natal day 14 (P14), there is no difference in total body 
weight between Raptor L/L and Raptor L/L Adipoq-cre mice (Figure 2.1A). The 
major subcutaneous and visceral perigonadal white adipose tissue depots 
(sWAT and pgWAT) are not significantly different in mass from controls at P14 
 
35 
(Figure 2.1B). The mass of other lean tissues such as the heart, kidney, and 
skeletal muscle is normal (Figure 2.1C). I confirmed Raptor loss by Western blots 
using whole sWAT and interscapular brown adipose tissue (iBAT) depots (Figure 
2.1D); the residual signal reflects the non-adipocyte population (see Section 3.2). 
Inactivation of mTORC1 activity was confirmed by decreased phosphorylation of 
the mTORC1 substrates 4E-BP1 (on phospho-T37/46) and ULK1 (on phospho-
S757), and by increased phosphorylation of AKT (on phospho-S473), which is 
caused by loss of the well-known mTORC1 mediated feedback inhibition of 
insulin/AKT signaling (Figure 2.1D) [4]. I also noted a slight decrease in total 
ULK1 protein in the KO tissues (Figure 2.1D).  
In post-natal development, the sWAT adipocytes exhibit characteristics of 
brown adipocytes including the presence of multi-locular lipid droplets and 
positive UCP1 expression (Figure 2.1D,E) [92, 93]. These adipocytes are called 
brite or beige adipocytes to distinguish them from classic brown adipocytes [94], 
and with age, they usually convert to or are replaced by more classic-looking 
unilocular white adipocytes. Raptor Adipoq-cre mice exhibit no defect in the post-
natal formation of brite/beige adipocytes in the sWAT as determined by UCP1 
protein expression (Figure 2.1D) and the appearance of multilocular adipocytes 
(Figure 2.1E). There is also no difference in the histological appearance of the 
pgWAT adipocytes or the liver at P14 (Figure 2.1E). Thus, Raptor is dispensable 
in white adipocytes for post-natal adipose tissue growth and normal adipocyte 
size, and for post-natal formation of brite/beige adipocytes in the sWAT.  
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In contrast, the interscapular and subscapular brown adipose tissue 
depots (iBAT and sBAT) of Raptor Adipoq-cre mice are reduced in mass by 37% 
and 48% respectively at P14 (Figure 2.1B). I also noted an increase in the 
number of brown adipocytes containing large lipid droplets in the Raptor KO BAT 
(Figure 2.1F). To test whether this phenotype is tissue autonomous, I deleted 
Raptor with Ucp1-Cre. This also results in a significant size reduction of the BAT 
depots (Figure S1A) and the heterogeneous appearance of larger lipid droplets 
(Figure S1B). Total body mass and individual WAT depot mass was normal in 
RaptorUcp1-Cre mice (Figure S1C, D). Thus, while adipocyte Raptor is 
dispensable for post-natal WAT growth, it is required autonomously in brown 
adipocytes for normal post-natal BAT growth and lipid droplet size.  
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Figure 2.1: 1) Adipocyte Raptor KO mice exhibit normal WAT mass and mild 
BAT defects early in life. (A) Body weight measurements of KO (n=6) and WT 
(n=6) mice at 14 days of age. (B) Fat tissue mass of KO and WT mice at 14 days 
of age. (n=6) (C) Lean tissue mass of KO and WT mice at 14 days of age. (n=6) 
(D) Western blots of whole tissue lysate from iBAT and sWAT depots for 
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indicated proteins. (E,F) Representative H&E images of tissues at indicated 
magnification. (Data were analyzed by Student’s t-test. Values expressed as 
mean ±SEM. *p < 0.05; **p < 0.01; ***p < 0.001).  
 
3.2. Adipocyte Raptor KO mice progressively develop lipodystrophy associated 
with hepatic steatosis and insulin intolerance.  
During the first 4 months of life, Raptor Adipoq-cre mice consuming a 
normal chow diet (NCD) tend to be slightly heavier than controls although this 
does not reach statistical significance at least by 12 weeks of age (Figure 2.2A, 
left). Raptor Adipoq-cre mice also tend to eat slightly more food but again this 
was not statistically significant (p value = 0.25) (Figure 2.2A, right). However, 
despite their relatively normal body weight, Raptor Adipoq-cre mice fail to expand 
their white adipose tissues with age. For example, the KO sWAT, retroperitoneal 
WAT (rWAT) and pgWAT are 35%, 37%, and 54% smaller respectively in the 
KOs compared to age matched controls (Figure 2.2B,C); KO BAT tissues also 
remained small (Figure 2.2B,C). Thus, adipocyte Raptor KO mice progressively 
develop lipodystrophy with age.  
We also confirmed Raptor loss and mTORC1 inactivation in whole sWAT 
and pgWAT depots from the 12-week old mice (Figure 2.2D). The residual 
Raptor signal is from stromal vascular fraction (SVF) cells as Raptor is virtually 
undetectable in purified mature adipocytes (Figure 2.2E). Histological analysis of 
the white adipocytes from 12-week old Raptor Adipoq-cre mice revealed a 
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heterogeneous size distribution pattern (Figure 2.2F). For example, pgWAT 
adipocytes in the Raptor Adipoq- cre mice show a bimodal distribution in which 
the relative number of small (<100 mM) and large (>200 mM) adipocytes is 
significantly increased compared to controls (Figure 2.2G). The mutant sWAT 
also contains two populations of adipocytes: a pool of large unilocular adipocytes 
and a pool of smaller adipocytes containing multiple lipid droplets (Figure 2.2F). 
Thus, with age the Raptor Adipoq-cre mice also cannot maintain normal 
adipocyte morphology.  
Strikingly, at 12-weeks of age there is also a 46% increase in liver mass in 
the Raptor Adipoq-cre mice compared to controls that is associated with a paler 
color suggesting hepatic steatosis (Figure 2.3A,B). The overgrowth of non-
adipose tissues is largely restricted to the liver as the mass of other lean tissues 
including the heart and skeletal muscles is unchanged (Figure 2.3A). I confirmed 
hepatic steatosis by Oil Red O staining, which revealed a marked increase in 
lipid staining in the KO (Figure 2.3C). Consistently, expression of the major de 
novo lipogenesis (DNL) enzymes ATP-citrate lyase (ACLY), Acetyl-CoA 
Carboxylase (ACC) and Fatty Acid Synthase (FASN) are also increased in 
Raptor Adipoq-cre KO livers (Figure 2.3D). Raptor Adipoq-cre KO mice are also 
insulin intolerant exhibiting a 54% increase in AUC in insulin tolerance tests 
(Figure 2.3E, top); glucose tolerance is normal (Figure 2.3E, bottom). Serum 
chemistry analysis indicates normal circulating free fatty acids (FFAs) (p = 0.77), 
circulating triacylglycerides (TAGs) (p = 0.0851) and cholesterol. 
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Figure 2.2: 2) Adipocyte Raptor KO mice develop lipodystrophy with age. (A) 
Body weight growth chart of WT (n = 6) and KO (n = 6) mice up to 12 weeks. 
Food intake of adult KO and WT mice. (B) Fat tissue mass of KO and WT mice at 
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12 weeks of age. (n=6) (C) Representative images of adult KO and WT mice, 
and indicated WAT and BAT depots. (D) Western blots from whole tissue lysate 
for indicated proteins. (E) Western blots from isolated mature adipocytes for 
indicated proteins. (F) Representative H&E images of WAT depots from KO and 
WT mice. (G) Distribution of adipocyte diameter (microns) in pgWAT depots from 
12 week old mice on chow diet. (n=6) (Data were analyzed by Student’s t-test. 
Values expressed as mean ±SEM. *p < 0.05; **p < 0.01; ***p < 0.001). 
 
3.3. Altered lipid metabolic pathways in adipocyte Raptor KO mice. 
The mTORC1 inhibitor rapamycin can stimulate lipolysis in cultured 
adipocytes [95, 96]. Therefore, I examined the major regulators of lipolysis in 
Raptor-deficient adipose tissues. I did not observe a significant increase in 
hormone sensitive lipase (HSL) phosphorylation between control and KO in 
pgWAT at 12 weeks of age; in fact it was slightly lower (Figure 2.2D). I also did 
not detect increased adipose triglyceride lipase (ATGL) protein levels in the 
sWAT of Raptor Adipoq-cre mice; however, I could detect a slight increase in 
ATGL in the pgWAT (Figure 2D) that correlated with a modest increase in basal 
glycerol release from tissue explants (Figure 2.4A). However, Atgl mRNA was 
decreased in both WAT depots (Figure 2.4B). Additionally, I examined regulators 
of lipogenesis. In the pgWAT of Raptor Adipoq-cre mice I detected significant 
increases in Acly (2.5 fold), Acc (2.1 fold), and Fasn (2.1 fold) mRNA (Figure 
2.4C left) and protein (Figure 2.2D). Similar increases occur in the sWAT 
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although only the increase in Acly mRNA reaches significance even though 
ACLY, ACC and FASN proteins are all elevated in this depot (Figures 2.2D, 2.4C 
right). Consistently, expression of Chrebpb, which encodes an isoform of 
ChREBP that potently induces transcription of the DNL genes [19], increases by 
124-fold and 48-fold in pgWAT and sWAT respectively (Figure 2.4D). This is 
interesting because although DNL contributes only a fraction to the total lipid pool 
of adipocytes, increased Chrebpb expression and DNL often correlate with 
insulin sensitivity [97] indicating this can be uncoupled in the Raptor Adipoq-cre 
mice. Moreover, while the mTORC1 substrate ULK1 is well known to control 
autophagy, in mature adipocytes it may have an additional role in lipogenesis 
downstream of mTORC1 as in vitro knockdown of Ulk1 in differentiated 3T3L1 
adipocytes increases Acc and Fasn expression [98]. Thus, in vivo Raptor loss in 
mature adipocytes alters the normal regulation of lipid metabolic pathways, 
possibly with depot-dependent variances.  
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Figure 2.3: 3) The progressive lipodystrophy of adipocyte Raptor KO mice 
associates with hepatic steatosis and insulin intolerance. (A) Lean tissue mass of 
KO and WT mice at 12 weeks of age. (n=6) (B) Representative images of liver 
from KO and WT mice at 12 weeks. (n=6) (C) Representative H&E images of 
liver from KO and WT mice. (n=6) (D) Western blots of liver lysate for indicated 
proteins. (E) ITT and GTT of adult KO and WT mice. (n=6) (F) Serum chemistry 
levels of FFA, TG, and Cholesterol for adult WT and KO mice on chow diet. (n=6) 
(G) Serum insulin levels for adult WT and KO mice. (H) Serum adiponectin levels 
for adult WT and KO mice. (n=6) (Data were analyzed by Student’s t-test. Values 
expressed as mean ±SEM. *p < 0.05; **p < 0.01; ***p < 0.001). 
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Figure 2.4: 4) Altered lipid metabolic pathways in the adipose tissues of 
adipocyte Raptor KO mice. (A) Concentration of glycerol from media of incubated 
excised pgWAT depots under specified conditions. (B) ATGL mRNA from whole 
tissue lysate. (n=6) (C) Acly, Acc, and Fasn mRNA expression in pgWAT and 
sWAT. (n=6) (D) Chrebpb mRNA expression in pgWAT and sWAT. (n=6) (Data 
were analyzed by Student’s t-test. Values expressed as mean ±SEM. *p < 0.05; 
**p < 0.01; ***p < 0.001). 
 
3.4. Raptor KO mice are resistant to diet-induced obesity but develop severe 
hepatic steatosis. 
We next asked whether Raptor Adipoq-Cre mice could increase their fat 
mass if placed on an obesogenic high fat diet (HFD). Beginning at 12-weeks of 
age, Raptor Adipoq-Cre mice and their age matched controls were switched onto 
a HFD for 8-weeks. Controls gained on average 9.4 g of body weight while in 
contrast Raptor Adipoq-Cre mice gained only 2.5 g resulting in a 14% difference 
in total body mass between the two cohorts after 8 weeks (Figure 2.5A). Body 
composition analysis indicates the weight difference was due to a 5-fold 
decrease in fat mass in the mutants, which notably also had slightly higher lean 
mass (Figure 2.5B). The difference in fat mass is clearly evident upon dissection 
(Figure 2.5C) and individual tissue mass measurements (Figure 2.5D). 
Comparing the average mass of individual WAT depots at the start and end of 
HFD feeding shows that control sWAT increases by 5.9-fold and pgWAT by 6.5-
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fold while the mutant sWAT and pgWAT barely grow, increasing by only 1.9-fold 
and 1.3-fold, respectively (Figure 2.5E). Interestingly, comparing individual 
adipocyte size at the start and end of HFD feeding indicates that the control and 
KO adipocytes in both depots increase in size although the size heterogeneity in 
the KO tissue is still apparent (Figure 2.5F). Thus, despite the inability of whole 
Raptor KO depots to expand on HFD, Raptor KO adipocytes appear to retain 
some ability to grow by hypertrophy.  
Importantly, at the conclusion of HFD-feeding, the livers of the KO mice 
are now ~80% larger than controls (as opposed to 46% larger at the start of 
feeding) resulting in a liver/body weight ratio that is now nearly twice of that of 
controls (Figure 2.5G,H,I). The livers of the KO mice also exhibit significantly 
more severe hepatic steatosis (Figure 2.5J). Muscle and heart mass remain 
unchanged between the cohorts (Figure 2.5G). Thus, the inability of adipose 
tissues to expand in HFD-fed Raptor Adipoq- Cre mice results in more 
redistribution of lipids to the liver.  
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Figure 2.5: 5) Adipocyte Raptor KO mice are resistant to HFD obesity but suffer 
from more severe hepatic steatosis. (A) Body weight, and weight gain of mice 
over course of HFD. (n=6) (B) Body weight and body composition after 4 weeks 
HFD. (C) Representative images of inguinal fat depots after HFD. (n=6) (D) 
Adipose depot masses at the end of HFD course. (n=6)  (E) Fold increase in 
WAT depot mass after HFD feeding. (n=6) (F) Representative H&E images of 
specified tissues before and after HFD. (n=6)  (G) Lean tissue mass after HFD. 
(H) Representative images of liver after HFD. (n=6)  (I) Liver/BW ratio of mice 
after HFD. (n=6) (J) Representative ORO staining of liver samples after HFD. 
(n=6) (Data were analyzed by Student’s t-test. Values expressed as mean ±SEM. 
*p < 0.05; **p < 0.01; ***p < 0.001). 
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3.5. Adipocyte Raptor KO mice have normal energy expenditure and a lipid 
absorption defect. 
Next I explored possible mechanisms by which deleting Raptor in 
adipocytes restricts adipose tissue growth. One possibility is that Raptor 
increases energy expenditure (EE), which protects against obesity. I reasoned 
that the severe hepatic steatosis and hepatomegaly observed in both chow and 
HFD fed Raptor Adipo-Cre cohorts argues against this scenario. However, the 
concept was previously proposed in a study that used aP2-Cre to delete Raptor 
in adipose tissue [61]. This study observed normal food intake but resistance to 
HFD and improved insulin tolerance in Raptor aP2-Cre mice and this was 
attributed to increased Ucp1 mRNA expression in pgWAT and elevated EE; 
hepatic steatosis and hepatomegaly was not observed in Raptor aP2-Cre mice. 
Indeed, I find that Ucp1 mRNA is increased in both the sWAT and pgWAT of 
Raptor Adipo-Cre mice consuming chow diet (Figure 2.6A). This correlates with 
elevated Pgc1a levels in sWAT, and elevated Cpt1 in both sWAT and pgWAT 
(Figure 6A). However, in chow fed mice UCP1 protein was barely detectable in 
either WAT depot (Figure 2.6B). Moreover, I could only detect a slight increase in 
UCP1 protein in the sWAT of HFD-fed Raptor Adipo-Cre mice after a long 
exposure (Figure 2.6B). This suggests that total UCP1 protein is only slightly 
elevated in the sWAT of Raptor Adipo-Cre mice.  
To better assess energy balance I contracted out metabolic cage 
experiments at the UMass Mouse Metabolic Phenotyping Center. I found no 
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difference in EE between HFD-fed Raptor Adipoq-cre mice and controls when 
expressing the data “per mouse” as recommend in [[94]] (Figure 2.6C). However, 
because it is often debated which method of reporting is correct, I provide the 
raw data in Table S1. I also found that the Respiratory Exchange Ratio (RER) is 
higher in Raptor Adipoq-cre mice indicating greater utilization of carbo- hydrates 
for fuel (Figure 2.6D). Raptor Adipoq-cre mice also exhibited normal physical 
activity (Figure 2.6E) yet interestingly, they are hyperphagic consuming nearly 
twice as much food as controls (Figure 2.6F). Hyperphagia is likely explained by 
the fact that HFD-fed Raptor Adipoq-cre mice have greatly reduced circulating 
leptin (Figure 2.6G). I also examined fecal lipids and found nearly twice the 
amount of lipid in the feces of Raptor Adipoq-cre mice (Figure 2.6H) indicating a 
lipid absorption defect. Thus, the mechanism causing resistance to obesity in 
Raptor Adipoq-Cre mice cannot be explained by decreased food intake or 
increased EE.  
Based on the increased EE reported in aP2-Cre;Raptor mice, it was 
suggested that adipose mTORC1 could be a potential target for anti- obesity 
drugs. However, our results indicate several important phenotypic differences 
compared to Raptor aP2-Cre mice (see detailed comparison in Table S2). These 
differences likely reflect recent data indicating that the aP2-Cre driver has limited 
efficiency for adipocytes and targets non-adipocytes such as endothelial cells 
[62, 88-91]. It would be interesting to identify the exact target cell/mechanism 
responsible for the beneficial metabolic effects of deleting Raptor with aP2-Cre. 
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Nevertheless, in light of our characterization of Raptor Adipoq-Cre mice, I would 
argue against prolonged targeting of mTORC1 in fat as a strategy to reduce 
obesity, though the effects of temporal or partial mTORC1 loss have not been 
thoroughly explored.  
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Figure 2.6: 6) Energy utilization and adipocyte transcriptional regulation. (A) 
mRNA expression levels from whole tissue lysate from Chow fed mice for 
indicated genes. (n=6) (B) Western blots of whole tissue lysate for indicated 
proteins from both chow and HFD mice, along with exposure times. SE is short 
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exposure, LE is long exposure. (C) Mean energy expenditure per mouse over 24 
hrs, with AUC. (n=6) (D) Mean respiratory exchange ratio per mouse over 3 
days, with AUC. (n=6) (E) Mean activity per mouse over 3 days, with AUC. (F) 
Daily food intake per mouse after 4 weeks on HFD. (n=6) (G) Serum leptin 
concentration after HFD. (n=6) (H) Fecal lipid content after 4 weeks HFD. (n=6) 
(I) PPARy mRNA expression levels in whole tissue lysate for respective mouse 
models. (n=6) (J) mRNA expression levels of PPARy targets in whole tissue 
lysate for respective mouse models. (n=6) (K) C/EBPa mRNA expression levels 
from whole tissue lysate for respective mouse models. (n=6) (L) Adiponectin 
mRNA expression from whole tissue lysate for respective mouse models. (n=6) 
(Data were analyzed by Student’s t-test. Values expressed as mean ±SEM. *p < 
0.05; **p < 0.01; ***p < 0.001). 
 
3.6. Decreased C/EBPα activity in Raptor-deficient WAT 
We next asked whether adipocytes require mTORC1 to maintain 
expression of Ppary, which encodes the master transcriptional regulator of 
adipocyte differentiation and function, and is a marker of adipocyte identity. I saw 
no significant changes in Ppary mRNA expression in the sWAT or pgWAT from 
Raptor Adipoq-Cre mice eating  chow or HFD (Figure 2.6I) suggesting Raptor is 
not required to maintain adipocyte identity per se. I also examined the expression 
of CD36 and Lpl, two Ppary targets. In chow fed mice, Lpl tended to be lower 
while CD36 unaffected (Figure 2.6J); in the HFD group, both genes are reduced 
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(Figure 6J). Thus, Ppary activity, particularly during high fat feeding, may be 
altered in Raptor KO adipocytes.  
In contrast to Ppary, expression of the Ppary co-regulator C/EBPα (the 
founding member of the CCAAT/enhancer-binding family) is greatly reduced in 
the sWAT of both chow and HFD-fed mice as well as in pgWAT, though to a 
lesser extent in this depot (Figure 6K). Interestingly, it was recently reported that 
C/EBPa in mature adipocytes is dispensable for terminal embryonic 
adipogenesis and adult adipocyte survival, but required for normal adipose tissue 
expansion during high fat diet feeding [21, 99]. C/EBPα also promotes 
adiponectin expression [100-102]. Indeed, adiponectin mRNA expression in WAT 
(Figure 6L) and circulating Adiponectin levels (Figure 3H) are greatly reduced in 
Raptor Adipoq-Cre mice. Thus, decreased C/EBPα activity provides a possible 
mechanism to explain why only older Raptor Adipoq-Cre mice are resistant to 
adipose tissue expansion.  
3.7. Comparison to human lipodystrophy  
Raptor Adipoq-Cre mice bear phenotypic resemblance to human patients 
suffering from congenital generalized lipodystrophy or Berardinelli-Seip 
lipodystrophy [103]. These patients suffer from adipose tissue loss, and similar to 
the Raptor Adipoq-Cre model, exhibit insulin resistance, hepatic steatosis, 
hypertriglyceridemia, and increased RER. Nearly a quarter of the patients 
develop diabetes mellitus. Other clinical features can include ectopic lipid in 
muscle and hypertrophic cardiomyopathy. Berardinelli-Seip lipodystrophy is 
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linked to mutations in AGPAT2 or BSCL2/seipin but the molecular basis of the 
disease is poorly understood. Interestingly, AGPAT2 and BSCL2 knockout 
models exhibit several phenotypic similarities to Raptor Adipoq-Cre mice [104-
106]. Moreover, the mTORC1 substrate Lipin-1, a phosphatidic acid phosphatase 
mutated in fatty liver dystrophy (fld) mice, was recently shown to physically 
interact with Seipin and AGPAT2 [45, 74, 75]. Thus, Raptor Adipoq-Cre mice 
may be useful in understanding the mechanistic basis of human congenital 
lipodystrophy.  
4. FUTURE DIRECTIONS AND CONCLUSIONS  
In this study I investigated the in vivo role of mTORC1 in mature 
adipocytes by deleting Raptor with Adiponectin-Cre. I conclude that mTORC1 
activity in white adipocytes is dispensable for early post-natal WAT growth, but 
becomes essential for normal adipose tissue expansion with age. Moreover, 
adipocyte Raptor KO mice consuming a high fat diet are hyperphagic yet 
resistant to obesity. However, despite increased Ucp1 mRNA expression in 
WAT, these mice are not protected from obesity due to increased energy 
expenditure. Rather, they appear to have a defect in adipose tissue expansion, 
which redistributes lipids to the liver resulting in severe hepatomegaly and 
hepatic steatosis, and causes a dietary lipid absorption defect. It does not appear 
that mTORC1 activity is required in WAT to maintain Pparg expression, but it 
may promote PPARy activity towards certain targets. I also find that mTORC1 is 
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required for normal C/ebpa and adiponectin expression providing a plausible link 
to the adipose tissue expansion defect in older mice.  
We found no obvious indication that adipocytes were dying in large 
numbers at least at the time-points examined. One hypothesis is that increased 
autophagy coupled with defective lipid metabolic pathways, perhaps in part 
through altered ULK1 and/or Lipin function, could cause defective triglyceride 
accumulation and/or adipose tissue wasting. Alternatively, mTORC1 in mature 
adipocytes may promote WAT expansion in older mice by regulating production 
of a pro-adipogenic paracrine signal. Interestingly, mTORC1 may have a unique 
function in neo-natal BAT development that requires further examination. 
Because mTORC1 has several known and putative substrates [47, 48] it will be 
important to continue delineating the expression and contributions of each 
downstream pathway in WAT maintenance in vivo using the most updated and 
precise genetic and metabolic strategies.  
We also found that mTORC1 loss did not impair the post-natal BAT-like 
character of sWAT. Interestingly, it was recently reported that rapamycin blocks 
the “browning” of WAT in adult mice by inhibiting mTORC1 in mature adipocytes 
[81, 82] suggesting there may be differential requirements for mTORC1 in post-
natal versus adult brite/ beige adipocyte formation. Moreover, another study 
reported that increased mTORC1 signaling in BAT promotes a brown-to-white 
phenotypic switch, and in this model, rapamycin reversed the “whitening” of BAT 
[36, 107]. Thus, the precise role of mTORC1 in BAT/WAT interconversions 
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remains to be seen. It should be noted that cold-challenge experiments are key 
in studying BAT, and that was not done in my animals. 
Notably, our conclusions are based on chronic (congenital) Raptor loss in 
adipocytes and thus the primary in vivo defect associated with losing mTORC1 
activity cannot be determined by this approach. Future studies utilizing tools that 
allow us to inhibit mTORC1 in a temporal manner will be key in better 
understanding primary and secondary responses to mTORC1 loss in adipose 
tissue. Moreover, it is clearly difficult to obtain the perfect Cre-driver for tissue-
specific KO studies, thus future advances may lead to additional refinements in 
understanding mTORC1 signaling in fat. Nevertheless, Raptor Adipoq-Cre mice 
exhibit phenotypic similarities to human patients suffering from congenital 
generalized lipodystrophy suggesting this model may have significant clinical 
implications. The next chapter will investigate acute vs chronic responses to 
mTORC1 loss, mechanisms that may contribute to metabolic dysfunction, and a 
study of upstream regulators involved with mTORC1 activation. 
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Supplementary Data: 
 
Figure 2.7.) Ucp1-Cre driven Raptor KO reveal similar BAT phenotype as 
Adipoq-Cre driven mice. (A) BAT depot mass in adult Ucp1-Cre Raptor L/L KO 
and WT mice. (n=6) (B) Representative H&E histology of adult WT and KO mice. 
(n=6) (C) Body weight of adult mice. (n=6) (D) WAT depot mass in adult mice. 
(n=6) 
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 Figure 2.8: Supplementary Table 1 – Raw Energy Expenditure data 
 
 
Parameter Examined 
 
 
Observed difference relative to control 
  
Raptor Adipoq-Cre 
 
 
RaptoraP2-Cre 
Total body mass Normal Reduced 
Adipose tissue mass Reduced Reduced 
Adipocyte Size Bimodal distribution Normal 
Liver mass Increased Normal 
Hepatic Lipids Increased Slightly decreased 
ITT Insulin Intolerant n.d. 
GTT Normal Normal 
Adiponectin Decreased Decreased 
Fasting Insulin No difference Decreased 
Leptin Chow (no difference) 
HFD (reduced) 
Chow (Decreased) 
HFD (decreased) 
Ucp1  Increased (sWAT & pgWAT) Increased (pgWAT only) 
UCP1 (protein)  Very low (sWAT);  
Undetectable (pgWAT) 
n.d. 
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Response to HFD Reduced adipose tissue 
growth; severe 
hepatomegaly and hepatic 
steatosis 
Reduced adipose tissue 
growth; no difference in 
hepatic steatosis 
Energy Expenditure (HFD) No change (normalized per 
mouse) 
Increased (normalized to 
0.75 power of total body 
weight) 
Food Intake (HFD) Increased  No difference 
Physical Activity (HFD) No difference Decreased 
Fecal Lipids (HFD) Increased No difference 
Basal Lipolysis in WAT 
(ex vivo) 
Slightly Increased 
(pgWAT) 
No difference 
Ppary  (mRNA) normal in vivo (mRNA) normal in vivo 
Cebpa Decreased No difference 
Chrebb Increased in sWAT & 
pgWAT 
n.d. 
DNL pathway (Acly, Acc, 
Fasn) 
mRNA & protein increased n.d. 
 
BOLD Indicates key differences between models 
n.d. Not determined 
ITT Insulin tolerance test 
GTT Glucose tolerance test 
HFD High fat diet 
sWAT Subcutaneous white adipose tissue 
pgWAT Peri-gonadal white adipose tissue 
 
Figure 2.9: Supplementary Table 2- A comparison between the Raptor Adipoq-Cre 
mice described in this study and previously described RaptoraP2-Cre mice  
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CHAPTER III: Adipose mTORC1 Regulates Adipose Tissue 
Health Independent of Autophagy-mediated Lipoatrophy, and 
Amino Acid Sensing RagGTPases. 
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INTRODUCTION:  
 In the previous chapter, I reported that the mechanistic target of 
rapamycin complex 1 (mTORC1) plays an important role in maintaining normal 
adipose tissue growth. mTORC1 is a metabolic node that integrates upstream 
indicators of energy availability and uses these inputs to act upon downstream 
targets that regulate anabolic pathways [28]. The specific loss of mTORC1 
signaling in mature, differentiated adipocytes of mice leads to the development of 
lipodystrophy that becomes evident as mice age into adulthood [77]. After 
several months of age, adipose-mTORC1 deficient mice suffer from numerous 
metabolic abnormalities such as severe hepatomegaly, insulin resistance, 
hyperphagy, and defective dietary lipid absorption. The underlying mechanism 
that lead to the lipodystrophy seen in adipose-Raptor KO mice was unclear. With 
a constitutive deletion, several factors may contribute to the progression of 
lipodystrophy, including interference with development, lipid accumulation, 
adipocyte differentiation, and adipocyte death. To better understand and model 
the role of adipocyte mTORC1 signaling in mature adipose tissue, I generated 
chemically inducible genetic models that allow us to specifically inhibit mTORC1 
signaling in mature adipocytes, at any point of development. This allows for mice 
to develop normally to adulthood before inhibiting mTORC1 activity, in a way 
mimicking signaling changes that may occur in obese patients [108] [109]. 
Ultimately this may be a useful model in understanding mechanisms that lead to 
adipose tissue malfunction in adult onset obesity.  
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I find that loss of mTORC1 signaling in adult mice leads to lipodystrophy 
over a prolonged period of time, similar to mTORC1 congenital deletion, while 
there are little to no metabolic changes in the short term. I find that acute loss of 
mTORC1 may induce pathways that in fact promote adipocyte survival, but 
chronic ablation leads to wasting of AT and evidence of adipocyte death. In 
conjunction with this loss of AT mass, I see increases in AT inflammation, hepatic 
steatosis, and insulin resistance. Interestingly, it appears that autophagic flux 
leads to wasting of AT and progressive lipoatrophy. I show that, using 
Atg7/Raptor dKO mice, this phenomenon is reversed when autophagy is 
inhibited, however, accompanying AT inflammation and steatosis persisted. 
These results suggest that adipose mTORC1 plays an important role in whole 
body metabolic homeostasis, independent of adipocyte capacity and AT mass.  
2. MATERIALS & METHODS  
2.1. Mice  
R26R-mTmG (stock 007676) were from Jackson Laboratory. Raptor floxed mice 
are described in [13] and were backcrossed 10 generations to C57BL/6J 
background mice from Jackson Laboratory and crossed to C57BL/6J mice 
expressing the Adiponectin-Cre driver or the Adiponectin-CreER driver (generous 
gifts of Evan Rosen). Doxycycline inducible KO mice were generated with Tre-
Cre Adiponectin-rtTA mice crossed with Raptor L/L. Both Cre control and Floxed 
Cre-negative mice were bred. Floxed-cre negative mice were used as controls. 
Male mice were used in experiments. Mice were kept on a daily 12 h light/dark 
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cycle and fed a normal chow diet (Prolab Isopro RMH 3000) from Lab Diet ad 
libitum at 22 C. All animal experiments were approved by the University of 
Massachusetts Medical School animal care and use committee.  
2.2. Drug inducible deletion 
Tamoxifen-inducible mice were treated with IP injection of 3 mg Tamoxifen per 
day (i.p.) for 6 constitutive days. Prolonged Tamoxifen treatment involved a 
single injection on a weekly basis, after initial 6-day treatment. Doxycycline 
inducible mice were fed a 600mg doxycycline/kg diet (Bioserv S4107), for 
indicated lengths of time.  
2.3. Antibodies and reagents  
Antibodies were purchased from Cell Signaling Technologies: ACC (3676), ACLY 
(4332), AKT (9727), P-AKT-S473 (4058), ATGL (2439), FASN (3180), HSL 
(4107), P-HSL-S660 (4126), ULK1 (8054), P-ULK1-S757 (6888), 4EBP1 (9644), 
P-4EBP1- S65 (9456), P-4EBP1-T37/46. UCP1 antibody was from AbCam (ab-
10983). Mitochondrial OxPhos antibody was from AbCam (ab110413) All other 
All other reagents were from Sigma Aldrich.  
2.4. Metabolic studies  
Serum samples were sent to the MMPC at the University of Cincinnati for 
analysis of circulating metabolites. For glucose tolerance tests (GTT) mice were 
fasted overnight (16 h) and then administered 2 g/kg of body weight of glucose or 
sodium pyruvate by intraperitoneal (i.p.) injection. For insulin tolerance tests 
(ITT), mice were fasted for 6 h before i.p. administration of 0.75 unit/kg of body 
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weight of insulin. Blood glucose concentrations were measured using a GE100 
blood glucose monitor, using blood vein collection before and after the injection 
at indicated time points.  
2.5. Tissue harvest and histology  
Adipose tissue depots were carefully dissected to avoid contamination from 
surrounding tissue. Samples for RNA or protein were snap frozen in liquid 
nitrogen and stored at 80°C until analysis. For histology, tissue pieces were fixed 
in 10% formalin. Embedding, sectioning, and Hematoxylin & Eosin (HE) staining 
was done by the UMass Medical School Morphology Core. For Oil Red O 
staining, liver samples were embedded in Optimal Cutting Temperature 
compound before sectioning and staining. For cell size measurements a 
minimum of 10 images were taken used per mouse. Image J was used to 
measure cell size and the distribution of cell size as percentage of total counted 
cells was analyzed.  
2.6. Adipocyte precursor cell (APC) isolation and FACS analysis 
Adipose progenitor cells (APC) were isolated as described in [19] : Stromal 
vascular fraction (SVF) was prepared from each fat pad by collagenase 
treatment and SVF pellets were resuspended in erythrocyte lysis buffer (0.15 M 
ClNH4, 0.01 M HCO3K in water). Cells were then pelleted by centrifugation, 
resuspended in staining media (HBSS + 2% FBS), and labeled with appropriate 
antibodies. After staining, cells were filtered through a 35-μm cell-strainer capped 
tube to ensure single cell suspension and stained with live/dead Blue. Live single 
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cells were gated according to the expression of surface markers 
(CD31−CD45−CD29+CD34+Sca1+)  in a BD LSRII analyzer. Data was analyzed 
with FlowJo. Markers: Live/dead Blue (Molecular Probes, L23105), CD31-PE-
CY7 (eBioscience, 25-0311), CD45-PE-CY7 (eBioscience, 25-0451), CD29-
AlexaFluor700 (Biolegend, 102218), CD34-AlexaFluor647 (Biolegend, 119314), 
Sca1-Pacific Blue (BD Bioscience, 560653), CD45-FITC (eBioscience, 11-0451)  
2.7. Adipocyte Labeling 
R26R-mTmG L/L (stock 007676) mice were crossed with Adiponectin-Cre Raptor 
L/L to generate Adiponectin Cre Raptor L/L mTmG L/L mice. Depots were 
dissected mounted whole and intact. Fragments were mounted with 
Fluoromount-G (Southern Biotech). Mounted samples were imaged the same 
day on a LSM 5 Pascal (Zeiss) point scanner confocal system. To acquire the 
images for quantification, a general survey of the entire tissue was first 
performed using a 10X objective to determine the uniformity of labeling 
throughout the tissue. Then, the tissue was subdivided into quadrants and a 40X 
oil immersion objective was used to obtain random images from each quadrant. 
Background fluorescence was offset using tissues from animals not carrying 
the R26R-mTmG reporter. tdTomato and eGFP settings were set using fat 
tissues from mice carrying the R26R-mTmG reporter and from adiponectin-
Cre;R26R-mTmG mice, respectively. eGFP was excited at 488 nm and detected 
from 515 to 565 nm. tdTomato was excited at 543 nm and detected from 575 to 
640 nm. 
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2.8. Western blots  
Tissue samples or cells were lysed in a buffer containing 50 mM Hepes, pH 7.4, 
40 mM NaCl, 2 mM EDTA, 1.5 mM NaVO4, 50 mM NaF, 10 mM sodium 
pyrophosphate, 10 mM sodium β-glycerophosphate and 1% Triton X-100. 
Tissues were homogenized using a TissueLyser (Qiagen) in the same lysis 
buffer supplemented with 0.1% SDS, 1% sodium deoxycholate. Equal amounts 
of total protein were loaded into acrylamide/bis-acrylamide gels and transferred 
to PVDF membranes for detection with the indicated antibodies. Membranes 
were incubated with primary antibodies in 5% milk/PBST or 5% BSA/PBST 
overnight. Membranes were then incubated for 1hr with HRP-conjugated 
secondary antibodies. Western blots were developed by enhanced 
chemiluminescence (PerkinElmer) and detected by X-ray films.  
2.9. Gene expression analysis  
Cells or tissues were lysed with Qiazol (Invitrogen) and total RNA was isolated 
with the RNeasy kit (Invitrogen). Equal amounts of RNA were retro-transcribed to 
cDNA using a High capacity cDNA reverse transcription kit (#4368813, Applied 
Biosystems). Quantitative RT- PCR was performed in 10 mL reactions using a 
StepOnePlus real- time PCR machine from Applied Biosystems using SYBR 
Green PCR master mix (#4309156, Applied Biosystems) according to 
manufacturer instructions. Relative mRNA expression was determined by the 
DCt method, and Tbp (TATA sequence binding protein) expression was used as 
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a normalization gene in all conventional RT- PCR experiments. Mouse primers 
used: 
Gene   Forward primer (5'-3')    Reverse primer (5'-3')  
Tbp   GAAGCTGCGGTACAATTCCAG  CCCCTTGTACCCTTCACCAAT  
Sreb1c   AAGCAAATCACTGAAGGACCTGG  AAAGACAAGCTACTCTGGGAG  
Chrebpα  CGACACTCACCCACCTCTTC   TTGTTCAGCCGGATCTTGTC  
Chrebpβ  TCTGCAGATCGCGTGGAG   CTTGTCCCGGCATAGCAAC  
Acly   CTCACACGGAAGCTCCATAA   ACGCCCTCATAGACACCATC  
Acaca   GGAGATGTACGCTGACCGAGAA  ACCCGACGCATGGTTTTCA 
Fasn   GCTGCGGAAACTTCAGGAAAT  AGAGACGTGTCACTCCTGGACTT  
Scd1   CCCTGCGGATCTTCCTTATC   TGTGTTTCTGAGAACTTGTGGTG  
Ppary1   TGAAAGAAGCGGTGAACCACTG  TGGCATCTCGTGTCAACCATG 
Ppary2   TGGCATCTCTGTGTCAACCATG  GCATGGTGCCTTCGCTGA 
Ucp1   CTGCCAGGACAGTACCCAAG  TCAGCTGTTCAAAGCACACA  
Ppargc1a CCCTGCCATTGTTAAGACC   TGCTGCTGTTCCTGTTTTC  
Lpl   GGCCAGATTCATCAACTGGAT  GCTCCAAGGCTGTACCCTAAG 
Prdm16  CACCTCTGTATCCGTCAGCA   CACCTCTGTATCCGTCAGCA  
Pgc1a  CCCTGCCATTGTTAAGACC  TGCTGCTGTTCCTGTTTTC 
Ucp1  CTGCCAGGACAGTACCCAAG  CTGCCAGGACAGTACCCAAG 
C/ebpα   CAAGCCCAGCAACGAGTACCG  GTCACTGGTCAACTCCAGCAC  
C/ebpβ  TCGGGACTTGATGCAATCC   AAACATCAACAACCCCGC  
C/ebpδ   GCTTTGTGGTTGCTGTTGAA   ATCGACTTCAGCGCCTACA  
aP2   GATGCCTTTGTGGGAACCT   CTGTCGTCTGCGGTGATTT 
Cidea   ATCACAACTGGCCTGGTTACG  TACTACCCGGTGTCCATTTCT  
Dpt   CTGCCGCTATAGCAAGAGGT  TGGCTTGGGTACTCTGTTGTC  
Srebf2   GGATCCTCCCAAAGAAGGAG  TTCCTCAGAACGCCAGACTT  
Tfam   GTCCATAGGCACCGTATTGC   CCCATGCTGGAAAAACACTT 
Cpt1b   GGGCACCTCTGGGAGTTTGT  TTGGCTCACCCACACAGTGT  
2.10. Statistics  
Unless otherwise stated, values given are mean  SEM. Two-way ANOVA was 
performed where indicated. For most experiments, un- paired two-tailed 
Student’s t test was used to determine statistical significance among two groups 
(*p < 0.05; **p < 0.01; ***p < 0.001).  
RESULTS: 
Adipose Raptor KO mice do not regain metabolic homeostasis:  
It was previously reported that adipose Raptor KO mice experience 
physiological changes in metabolic function such as reduced fecal lipid uptake 
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and increased RER, and development of lipodystrophy [77]. To see whether or 
not these physiological changes were adaptive in order to reestablish metabolic 
homeostasis and possibly sufficient to overcome Raptor loss, I allowed 
conditional Raptor KO to reach 1 year of age. I found these mice are unable to 
compensate for the loss of Raptor in mature adipocytes. These mice suffer from 
increased severity of lipodystrophy with extremely small adipose tissue depots, 
including a near absence of visceral WAT (Figure 3.1A-B), along with evidence of 
adipose tissue necrosis in both brown and white depots (Figure 3.1C). The mice 
suffer from extreme splenomegaly and hepatomegaly, with masses at least 2-fold 
greater than control mice (Figure 3.1D). In addition, I see development of tumors 
in these enlarged livers in 7/9 mice (Figure 3.1F). Despite depletion of adipose 
tissue depots as a whole, there are still adipocytes that remain and appear to be 
viable. To understand whether or not these remaining adipocytes were in fact 
targeted by the Adiponectin-Cre, I crossed in a fluorescent reporter that labels 
with GFP all cells that express Adiponectin-Cre. Using this tool, I found that in 
Adiponectin-Cre Raptor L/L mTmG L/L mice, the adipose depots are labeled with 
near 100% efficiency (Figure 3.1E).  
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Figure 3.1: 1) Adipose Raptor KO adipocytes are universally targeted, and KO 
mice are unable to metabolically adapt as they age. A-B) Body weight and tissue 
weight of control, and Adiponectin-Cre Raptor L/L mice at >1yr of age (n= 9) C) 
Representative H&E staining of respective tissues (n=9) D) Lean tissue mass 
(n=9) E) GFP/RFP imaging of mTmG floxed mice, and Adiponectin-Cre Raptor 
L/L mTmG L/L mice (n=6) F) Example of a diseased liver with tumor from KO 
mouse (n=9) (Data were analyzed by Student’s t-test. Values expressed as mean 
±SEM. *p < 0.05; **p < 0.01; ***p < 0.001). 
 
Inducing Raptor deletion in healthy adult mice causes a similar progressive 
lipodystrophy 
To better understand the role of Raptor signaling in fully developed, adult 
mice, I generated two chemically inducible systems to delete Raptor in mature 
adipocytes. One commonly used model is a tamoxifen-dependent CreER 
recombinase, although there are concerns regarding lipotoxicity with tamoxifen 
[110]. Another model is a tetracycline-dependent Tet-On system, although the 
use of doxycycline may affect mitochondrial health, gut microbiome, and I find 
the labeling to be incomplete in adipocytes when paired with Adiponectin-Cre 
(Figure 3.3C). Nevertheless, both systems offer advantages in the study of 
Raptor deletion in adult mice. In an acute setting, both tamoxifen and doxycycline 
treatment had no effect on the mice, in contrast to other models such as a 
tamoxifen-induced double KO of IR and IGF1 [87]. Over time, however, such as 
 
71 
at 4wks of deletion with tamoxifen, I began to see mild changes in WAT depot 
size and adipocyte diameter, although there is no apparent metabolic phenotype 
yet at this point (Figure 3.2A, E). With the CreER system and utilizing mTmG 
labeling, I find very efficient labeling in the AT depots, with roughly 95% labeling 
in SAT and 90% in VAT within a week after tamoxifen injection. Over time this 
labeling remains strong with 90% and 85% respectively at 5 weeks (Figure 3.2B). 
To better understand a chronic loss of Raptor in adult mice, I used the 
doxycycline inducible Tet-On mice to avoid issues such as toxicity with 
tamoxifen, and the chronic stress of exposing mice to long term IP injections of 
tamoxifen over the course of 10 weeks. Despite incomplete labeling (Figure 
3.3C), I see that after 10wks of doxycycline treatment, these mice begin to suffer 
from lipodystrophy, altered adipocyte size in vivo, with a corresponding 
hepatomegaly and metabolic defect in insulin sensitivity, similar to what was 
seen with a constitutive adipose specific deletion of Raptor (Figure 3.2C-E) [77].  
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Figure 3.2 2) In vivo, metabolic consequences arise weeks after inducing Raptor 
deletion. A) Tissue mass and adipocyte size distribution of adult mice treated 
 
73 
with tamoxifen for 5 weeks. (n=6) B) mTmG labeling of control and KO mice 
treated with tamoxifen for indicated times (n=3) C) Tissue mass and adipocyte 
size distribution of adult mice treated with doxycycline for 10 weeks (n=6) D) 
Representative H&E imaging of adipose tissue from KO mice treated with 
doxycycline for 10 weeks (n=6) E) ITT for indicated mice. (n=6) (Data were 
analyzed by Student’s t-test. Values expressed as mean ±SEM. *p < 0.05; **p < 
0.01; ***p < 0.001). 
 
Adipocyte differentiation is preserved in acute Raptor deletion, while 
chronic deletion leads to adipocyte death  
 As mentioned earlier, contributing factors to lipodystrophy may include 
impaired lipid accumulation, disruption of adipocyte differentiation, and increased 
adipocyte cell death [111]. Using a cell culture model, I am able to delete Raptor 
after adiponectin expression during adipocyte differentiation, mimicking the 
adipocyte differentiation process of the KO mice in vivo (Figure 3.3A). In vitro, 
adipocytes are able to differentiate and accumulate lipids despite Raptor loss 
(Figure 3.3B). Additionally, sorting for cell surface markers of the stromal 
vascular fraction from WAT depots show that KO mice do not have a deficiency 
in adipose precursor cells. Overtime, in the setting of incomplete adipocyte 
targeting, adipocytes that are not targeted for deletion have a competitive 
advantage that lead to a recovery of the AT (Figure 3.3C). Utilizing doxycycline 
inducible Raptor KO animals with the mTmG reporter, I see significant 
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repopulation with a majority of untargeted, RFP labeled, cells (Figure 3.3C). With 
this recovery in adipose tissue mass is also a recovery in liver mass, and insulin 
sensitivity, suggesting that Raptor KO induced lipodystrophy and associated 
metabolic disfunction may be recovered given the presence of normal adipocytes 
(Figure 3.3D). In the setting of Raptor KO induced lipodystrophy, however, the 
adipose tissue depots of these mice develop evidence of adipocyte death as 
seen by presence of atrophied GFP labeled cells in reporter mice, TUNEL 
staining, and presence of Crown like structures (CLS) (Figure 3.3C, E, F). 
Additionally, as has been reported previously, adipocyte specific Raptor deletion 
results in inflammation and increased macrophage markers within the adipose 
tissue (Figure 3.3G) [112]. 
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Figure 3.3: 3) Evidence of chronic cell death in Raptor KO adipose tissue 
depots. A) Mice that were fed doxycycline diet for 18 weeks recover their 
metabolic phenotype, with a recovery in WAT mass, liver mass, and ITT. (n=6) B) 
Acutely, the Tet-On system partially labels WAT. Following overtime, nontargeted 
adipocytes accumulate and comprise the majority of the tissue depot (n=3) C) In 
adult mice treated with doxycycline for 10 weeks, there is a significantly 
increased number of crown like structures in both SAT and VAT (n=6) D) Tissue 
mass and metabolic data of mice fed doxycycline diet for 18 weeks (n=6) E) 
TUNEL staining of indicated AT depots, showing increased TUNEL positive cells 
in KO animals (n=6) F) Increased evidence of crown-like structures in KO 
animals (n=6) G) qPCR for markers of inflammation and macrophage infiltration 
in sWAT. (Data were analyzed by Student’s t-test. Values expressed as mean 
±SEM. *p < 0.05; **p < 0.01; ***p < 0.001). 
 
Raptor loss in vivo impairs autophagy inhibition, while also associating 
with a decrease in mitochondrial mass. Paradoxically, mitochondria are 
significantly larger in KO tissues 
 AT depots taken from KO mice show significantly increased LC3II levels, 
indicating increased autophagic flux (Figure 3.4A). This is consistent with 
literature indicating the role of mTORC1 signaling in inhibiting autophagy through 
regulation of ULK1 phosphorylation [113]. In normal mice, I see that autophagy is 
particularly downregulated after feeding, this downregulation is uninhibited in 
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knockout animals (Figure 3.4A). I hypothesized that an increase in autophagic 
flux may play a role in progressive cell death by excessive scavenging of 
important intracellular organelles. I examined markers of mitochondrial content in 
the AT of these KO animals. Associated with this increase in autophagy is a 
decrease in mitochondrial mass. Both western blot for mitochondria associated 
proteins and qPCR for mtDNA show decreased mitochondrial markers from AT 
depots of KO mice (Figure 3.4B,C). Interestingly, when visualizing the 
mitochondria by TEM, the adipocyte mitochondria of KO animals are significantly 
larger by several fold (Figure 3.4D). I hypothesized this may be due to the role 
that mTORC1 plays in mitochondrial dynamics, in particular its role in regulation 
of mitochondrial fission dynamics [114]. I find that indeed a mitochondrial fission 
protein DRP1 appears to be in its inactive state (p-DRP1 S637), indicating a 
decrease in mitochondrial fission ability (Figure 3.4E).  
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Figure 3.4: 4) mTORC1 exhibits control over mitochondrial size and 
maintenance in adipose tissue. A) Western blot of control and Raptor KO mice 
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indicated increased autophagy in KO animals. B-C) Gene and protein markers 
indicating reduced mitochondrial mass in KO animals (n=6)D) Transmission 
election microscopy of BAT and SAT showing large individual mitochondria in KO 
tissues, with evidence of increased autophagic bodies and disorganized 
mitochondria. (Data were analyzed by Student’s t-test. Values expressed as 
mean ±SEM. *p < 0.05; **p < 0.01; ***p < 0.001). 
 
 
Acute response to Raptor deletion in vitro induces mitochondrial growth, 
increased autophagic flux, and resistance to classical apoptotic cell death. 
 In order to better understand the timeline of metabolic responses to 
deletion of Raptor, I isolated primary preadipocytes from UBC-CreER Raptor L/L 
mice. This allows us to inducibly delete Raptor (via tamoxifen treatment) in cell 
culture at specific points in adipocyte differentiation, as previously described 
(Figure 3.3). While deletion before treating with induction media blocks adipocyte 
differentiation, lipid accumulation and storage is maintained when Raptor is 
ablated after initiation of the differentiation process (Figure 3.5A). Contrary to 
what is seen in vivo after chronic inhibition, I see an acute increase in markers of 
mitochondrial mass, both by qPCR and western blot (Figure 3.5A). Consistently, 
however, I find a decrease in DRP1 activity and corresponding increase in 
mitochondrial size of the KO cells, again suggesting mitochondrial fission is 
acutely perturbed(Figure 3.5B,C). Additionally, I see evidence of increased 
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autophagic flux in the KO cells (Figure 3.5B), consistent with findings of 
increased late autophagic markers (LC3-II levels) in adipose tissue from KO 
animals. While chronic deletion in vivo leads to evidence of adipocyte death, KO 
cells in culture do not have accelerated death, and in fact appear to be resistant 
to apoptotic cell death, with decreased PARP and Caspase-3 cleavage when 
treated with staurosporine (Figure 3.5D). This phenomenon has been reported, 
and it has been suggested that increased autophagy may play a role in 
preventing apoptotic cell death in the short term [115].  
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Figure 3.5: 5) Contrasting changes in mitochondria in response to acute Raptor 
inhibition in vitro A) Gene and protein markers indicating increased mitochondrial 
mass after acute deletion of Raptor in vitro. B) Immunofluorescent labeling of 
mitochondria in vitro indicating increased mitochondrial size after acute Raptor 
deletion. C) Western blot showing increased phosphorylation at the inhibiting site 
of mitochondrial fission protein DRP1 D) Representative images and western 
blots from cell lysates after treatment with apoptotic promoting staurosporine 
(Data were analyzed by Student’s t-test. Values expressed as mean ±SEM. *p < 
0.05; **p < 0.01; ***p < 0.001). 
 
Lipoatrophy is rescued by inhibiting autophagy in the setting of Raptor KO 
mice, however AT inflammation and hepatosteatosis persist.  
 While Raptor KO cells may be resistant in vitro to acute stimulation of cell 
death pathways, chronic inhibition leads to adipocyte death in vivo. In both 
cases, elevated levels of autophagic flux are evident, a mechanism that may be 
involved in eventual atrophy of the AT. To test this I generated Adiponectin-Cre 
driven double KO mice Raptor and ATG7, a key autophagic protein. I find that 
blocking the upregulated autophagic flux due to Raptor loss helps restore overall 
adipose tissue mass in these animals [Figure 3.6A]. WAT depots return to normal 
size, and surprisingly iBAT depots become significantly larger than even in 
control animals [Figure 3.6A]. Despite this recovery in AT capacity, livers from 
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double KO mice still appear to suffer from steatosis as seen by Oil Red O 
staining, and liver TG analysis [Figure 3.6B]. Consistent with Raptor KO mice, 
the glucose sensitive ChREBP – DNL pathway appears to be upregulated 
[Figure 3.6C]. Additionally, restoration of AT mass and capacity in this case does 
not appear to alleviate adipose tissue inflammation seen as a result of adipose 
Raptor deletion, as indicated by increased qPCR markers of inflammation and 
macrophage infiltration [Figure 3.6D]. 
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Figure 3.6: 6) Inhibition of autophagy in Raptor KO rescues adipose tissue 
mass, but not hepatic steatosis of AT inflammation. (n=4) A) Tissue mass of 
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Control, Adiponectin-Cre driven Raptor KO, ATG7/Raptor dKO, and ATG7 KO 
mice. (n=4) B) Oil Red O staining of livers from indicated mouse strains and liver 
TG content with quantification of ORO signal (n=4) C) Western blots from iBAT 
and sWAT of WT and KO animals for proteins indicated. (n=4) D) qPCR markers 
for genes indicated from iBAT and sWAT of WT and KO animals. (n=4) (Data 
were analyzed by Student’s t-test. Values expressed as mean ±SEM. *p < 0.05; 
**p < 0.01; ***p < 0.001). 
 
DISCUSSION:  
 Loss of Raptor in all mature adipocytes has been shown to induce a 
progressive lipodystrophy apparent in adult, but not young, mice [77]. It has also 
been shown that Raptor is essential for brown adipose tissue expansion and 
adaptation to cold environment [76]. Previously, it was noted that lipodystrophic 
mice in the setting of Adiponectin-Cre driven Raptor deletion experienced 
physiological changes such as increased fecal lipid excretion, and increased 
RER, indicating a possible metabolic shift towards carbohydrate utilization [77]. I 
hypothesized that such metabolic changes may be an adaptive response to the 
lipodystrophy to reestablish a metabolic homeostasis, however, it is now clear 
that these adaptations are insufficient to restore a metabolic homeostasis in the 
setting of chronic adipocyte Raptor inhibition. mTORC1 signaling in mature 
adipocytes is critical for the maintenance of metabolic health throughout the 
lifespan of an adult mouse. 
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 Chronic nutrient excess begets extreme adipose tissue growth (obesity), 
which then leads to metabolic complications including common diseases such as 
insulin resistance, hepatosteatosis, and coronary heart disease [1, 11]. At the 
same time, an inability of adipose tissue to expand, lipodystrophy, also leads to 
very similar metabolic consequences [111, 116, 117]. The normal development 
and maintenance of adipose tissue is necessary for the appropriate storage of 
lipids in order to prevent energy stress on other organs in the body. Interestingly, 
in both settings, mTORC1 signaling has shown to play a role. In obese humans, 
there is evidence of impaired mTORC1 activity [108, 109]. Concurrently, in 
lipodystrophic humans, there is evidence of mutations that may also be related to 
mTORC1 [72, 73]. In the setting of Raptor-ablation induced lipodystrophy, I show 
that acute deletion of mTORC1 is generally benign, both in vitro and in vivo. In 
vitro, KO mature adipocytes retain their ability to accumulate and store lipids in 
the setting of up to 14 days. In fact, these KO cells appear to be resistant to 
classical, Caspase-3 driven apoptosis. This may be related to an upregulation in 
autophagic flux, as it is understood that autophagy is regarded as a mechanism 
that promotes cell survival, and may inhibit caspase mediated apoptosis [118] 
[119]. In vivo, acute inhibition of mTORC1 in adult mice similarly has little effect 
on adipose tissue mass and adipocyte morphology. In concordance, these mice 
do not appear to suffer from metabolic disturbances such as insulin resistance or 
hepatic steatosis. 
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 When deletion is induced for a longer period of time, however, I see that 
the adipose tissue begins to experience dysfunction, and metabolic 
consequences arise. Again, it’s evident that inhibition of mTORC1 signaling plays 
a critical role in the long-term maintenance of adipocytes, however it is largely 
dispensable in the short term. In the setting of a chronic, 10wk induced deletion, I 
show the development of lipoatrophy in conjunction with metabolic changes seen 
in the lipodystrophic congenital KO model. Also contrasting the acute deletion, 
chronic inhibition of mTORC1 leads to evidence of adipocyte death in vivo, 
including evidence of crown-like structures, increased signal upon TUNEL 
staining, adipose tissue inflammation, and atrophy of GFP positive cells using the 
mTmG reporter. Furthermore, given an abundant population of normal 
adipocytes, mice are able to recover from a transient state of metabolic function 
as the adipose tissue is able to regenerate. I present this in the doxycycline 
inducible model, where inefficient deletion allows for the adipose tissue depots to 
repopulate overtime with untargeted cells, reestablishing their ability to store 
lipids and maintain metabolic homeostasis.  
 Given the understanding of mTORC1’s role in inhibiting autophagy, and 
our data indicating increased autophagic flux in KO adipocytes, I hypothesized 
that the progressive lipoatrophy and adipocyte death may be related to chronic 
and unregulated increases in autophagy. Here I present that deleting a key 
autophagic protein ATG7 in the setting of Raptor KO does restore overall 
adipose tissue mass in adult mice. However, this restoration in AT capacity does 
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not appear to alleviate other metabolic changes such as hepatic steatosis and AT 
inflammation. These results suggest that while AT capacity to store lipids may be 
critical for metabolic homeostasis in many models, mTORC1 signaling in 
adipocytes may play key roles in regulating whole body metabolism that remain 
independent of lipid storage capacity. I would argue that lipid sequestration is 
only one of multiple key roles that adipose tissue plays in metabolic regulation.  
 In conclusion, I present that acute inhibition of mature adipocyte mTORC1 
activity by chemically inducible genetic ablation of Raptor has little to no 
metabolic consequence in the short term. Cultured adipocytes accumulate and 
maintain lipid droplets after ablation, as do adipose tissue depots of inducible KO 
animals. Over time, on the order of weeks, adipose tissue depots begin to 
atrophy, and KO animals present with evidence of adipocyte cell death. 
Associated with this change in adipose is an increase in liver size, and metabolic 
dysfunction as reported by insulin tolerance tests. Like the congenital model 
previously reported, it appears there is a redistribution of lipid storage from 
adipose to other organs, namely the liver. The chronic progression of lipoatrophy 
death seen in Raptor KO animals is likely related to the upregulation of 
autophagic flux, due to the loss of mTORC1 inhibition of autophagy. Inhibition of 
autophagy, through genetic ablation of adipose Atg in conjunction with Raptor 
rescues AT mass maintenance, but not corresponding metabolic changes such 
as hepatic steatosis and AT inflammation. Rather, these mice share some similar 
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changes in adipocyte morphology, however, they do not suffer from lipodystrophy 
or metabolic dysfunction.  
Overall, it is clear that mTORC1’s regulation of autophagic flux is critical 
for maintenance of adipose tissue in adult mice. Maintenance of AT mass by this 
pathway, however, is not sufficient to restore all metabolic anomalies seen in 
Raptor KO mice. It is possible that mTORC1 affects other pathways within 
adipocytes that are important in signaling to peripheral metabolic organs, such as 
regulation of adipose tissue inflammation, or production of circulating adipokines. 
Given the evidence of aberrant mTOR signaling in human obese patients, further 
studies on the changes that occur with adipocyte mTORC1 signaling in the 
context of obesity may play a critical role in understanding the development of 
metabolic syndrome.  
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CHAPTER IV: RagGTPases are dispensable for mTORC1 in adipose 
tissue. RagA and RagB have an mTORC1 independent role in regulating 
Ucp1 activity in WAT 
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INTRODUCTION: 
One of the goals set at the beginning of this project was to better 
understand how amino acid sensing through the RagGTPases control adipose 
tissue health and function. Based on the literature, it is believed that RagGTPase 
activity is a required step in the activation of mTORC1 [120-122]. Multiple in vitro 
studies have shown that eliminating the RagGTPases is sufficient to inhibit 
downstream mTORC1 signaling even in the presence of other stimulating factors 
[30, 34, 46, 121-123]. As mentioned earlier, the model is that for downstream 
activity, mTORC1 must be localized at the lysosomal membrane. Here it is 
directly activated by Rheb, whose activity is controlled by the TSC complex, a 
GAP regulated by the insulin/AKT signaling pathway. While the majority of 
signaling studies have been conducted in cancer cell models, there is scant data 
on the implications of tissue specific loss of RagGTPase activity in vivo [121].  
 Based on my findings of mTORC1 loss in adipose tissue, I hypothesized 
that RagGTPase activity in adipose tissue is critical for adipocyte health, and that 
loss of adipocyte Rags would lead to lipodystrophy and metabolic dysfunction. I 
expected that, using Adiponectin-Cre to delete Rag, I would find these mice to 
phenocopy mice with mTORC1 loss. To test this, I first generated Adiponectin-
Cre RagA L/L mice. Despite there being two different functional RagGTPase 
pairs (RagA/C, and RagB/D), it is believed that RagA is the most abundant, and 
most important for mTORC1 activity [121]. In fact, it was shown that RagB was 
not essential for embryonic development in mice.  
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 Surprisingly, I found that Adiponectin-Cre RagA L/L mice were 
phenotypically normal, with no defects in adipose tissue mass, or metabolic 
function. Additionally, mTORC1 signaling in the adipose tissue appeared to be 
intact. Absence of metabolic dysfunction or impaired mTORC1 signaling was 
maintained even when these mice were put through environmental stressors, 
such as high-fat diet, and thermoneutrality. These results suggested that either 
mTORC1 in adipocytes in fact does not require RagGTPase activity, or perhaps 
RagB/D alone are sufficient to sustain mTORC1 signaling under normal 
conditions. To address the possibility of RagB compensation, I then generated 
Adiponectin-Cre RagA RagB dKO mice. While these mice do not suffer from 
metabolic deficiency or lipodystrophy, they do exhibit stronger inhibition of 
downstream mTORC1 signaling accompanied by phenotypic changes in the 
adipose tissue, particularly in BAT.  
 Overall, these findings were surprising given the model that RagGTPases 
are required for mTORC1 activity. My results suggest that in vivo, adipocyte 
mTORC1 activity may be maintained absent RagA and RagB. Furthermore, there 
may be mTORC1 independent roles for the RagGTPases, particularly in 
relationship with Ucp1 expression in white adipocytes.  
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MATERIALS & METHODS  
2.1. Mice  
RagA floxed and Rag B floxed mice (generously donated by Alejo Efeyan) were 
backcrossed 10 generations to C57BL/6J stock mice from Jackson Laboratory 
and crossed to C57BL/6J mice expressing the Adiponectin-Cre driver. Male mice 
were used for experiments. Mice were kept on a daily 12 h light/dark cycle and 
fed a normal chow diet (Prolab Isopro RMH 3000) from Lab Diet ad libitum at 22 
C. All animal experiments were approved by the University of Massachusetts 
Medical School animal care and use committee.  
2.2. Antibodies and reagents  
Antibodies were purchased from Cell Signaling Technologies: ACC (3676), ACLY 
(4332), AKT (9727), P-AKT- S473 (4058), ATGL (2439), FASN (3180), HSL 
(4107), P-HSL-S660 (4126), ULK1 (8054), P-ULK1-S757 (6888), 4EBP1 (9644), 
P-4EBP1- S65 (9456), P-4EBP1-T37/46 (2855), RAGA (4357), RAPTOR 
(24C12). All other reagents were from Sigma Aldrich.  
2.3. Tissue harvest and histology  
Adipose tissue depots were carefully dissected to avoid contamination from 
surrounding tissue. Samples for RNA or protein were snap frozen in liquid 
nitrogen and stored at 80° C until analysis. For histology, tissue pieces were fixed 
in 10% formalin. Embedding, sectioning, and Hematoxylin & Eosin (HE) staining 
was done by the UMass Medical School Morphology Core. For Oil Red O 
staining, liver samples were embedded in Optimal Cutting Temperature 
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compound and frozen before sectioning and staining. For cell size 
measurements a minimum of 10 images were taken used per mouse. Image J 
was used to measure cell size and the distribution of cell size as percentage of 
total counted cells was analyzed.  
2.4. Western blots  
Tissue samples or cells were lysed in a buffer containing 50 mM Hepes, pH 7.4, 
40 mM NaCl, 2 mM EDTA, 1.5 mM NaVO4, 50 mM NaF, 10 mM sodium 
pyrophosphate, 10 mM sodium b-glycerophosphate and 1% Triton X-100. 
Tissues were homogenized using a TissueLyser (Qiagen) in the same lysis 
buffer supplemented with 0.1% SDS, 1% sodium deoxycholate. Equal amounts 
of total protein were loaded into acrylamide/bis-acrylamide gels and transferred 
to PVDF membranes for detection with the indicated antibodies. Membranes 
were incubated with primary antibodies in 5% milk/PBST or 5% BSA/PBST 
overnight. Membranes were then incubated for 1hr with HRP-conjugated 
secondary antibodies. Western blots were developed by enhanced 
chemiluminescence (PerkinElmer) and detected by X-ray films.  
2.5. Diet & metabolic studies  
At 10-12 weeks of age, male mice were placed on a 60% high fat diet (HFD) 
(D12492 Harlan Laboratories) for 8 weeks. Body weight was recorded weekly. 
Serum samples were sent to the MMPC at the University of Cincinnati for 
analysis of circulating metabolites. For glucose tolerance tests (GTT) mice were 
fasted overnight (16 h) and then administered 2 g/kg of body weight of glucose or 
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sodium pyruvate by intraperitoneal (i.p.) injection. For insulin tolerance tests 
(ITT), mice were fasted for 6 h before i.p. administration of 0.75 unit/kg of body 
weight of insulin. Blood glucose concentrations were measured using a GE100 
Blood Glucose monitor. Blood was from tail vein collection before and after the 
injection at indicated time points.  
2.6. Gene expression analysis  
Cells or tissues were lysed with Qiazol (Invitrogen) and total RNA was isolated 
with the RNeasy kit (Invitrogen). Equal amounts of RNA were retro-transcribed to 
cDNA using a High capacity cDNA reverse transcription kit (#4368813, Applied 
Biosystems). Quantitative RT- PCR was performed in 10 mL reactions using a 
StepOnePlus real- time PCR machine from Applied Biosystems using SYBR 
Green PCR master mix (#4309156, Applied Biosystems) according to 
manufacturer instructions. Relative mRNA expression was determined by the 
ΔCt method, and Tbp (TATA sequence binding protein) expression was used as 
a normalization gene in all conventional RT- PCR experiments. Mouse primers 
used: 
Gene   Forward primer (5'-3')    Reverse primer (5'-3')  
Tbp   GAAGCTGCGGTACAATTCCAG  CCCCTTGTACCCTTCACCAAT  
Ucp1   CTGCCAGGACAGTACCCAAG  TCAGCTGTTCAAAGCACACA  
2.7. Statistics  
Unless otherwise stated, values given are mean  SEM. Two-way ANOVA was 
performed where indicated. For most experiments, unpaired two-tailed Student’s 
t test was used to determine statistical significance among two groups (*p < 0.05; 
**p < 0.01; ***p < 0.001).  
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RESULTS 
Adipose specific RagA KO mice are phenotypically normal, with evidence 
of increased Ucp1 expression in WAT 
Primary adipocyte precursor cells were isolated from inguinal adipose 
tissue depots of wildtype C57BL/J mice. The cells were plated and differentiated 
into mature adipocytes in culture. After differentiation, cells were deprived of 
nutrients for 2 hours, then stimulated with either insulin alone, or insulin and 
amino acids. Phosphorylation of downstream mTORC1 target S6K appears to be 
dependent on amino acids, while 4EBP appears to be partially dependent. 
Phosphorylation of insulin signaling dependent AKT is unchanged in AA deprived 
or supplemented conditions [Figure 4.1A]. Adiponectin-Cre RagA L/L mice were 
generated, and allowed to grow to 10 weeks of age under chow diet, at standard 
(22°C) housing conditions. Adipocyte RagA knockout mice did not appear to 
have any changes in BAT or WAT depot size, or lean tissue mass [Figure 4.1B]. 
Adipocytes in both BAT and WAT depots appeared to be morphologically normal 
[Figure 4.1D]. Despite efficient RagA deletion, downstream mTORC1 
phosphorylation targets do not appear to be changed. Phosphorylation of AKT, 
commonly seen to be elevated in Raptor KO mice, was also unchanged [Figure 
4.1C]. Notably, there was a persistent increase in Ucp1 expression, both in 
protein and mRNA, in the sWAT depot [Figure 4.1E]. Overall, adipocyte RagA 
deletion did not adversely affect metabolic function [Figure 4.1F].  
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Figure 4.1: Adipose specific RagA KO mice are phenotypically normal, with 
evidence of increased Ucp1 expression in WAT A) Western blots of primary 
adipocytes differentiated in culture, stimulated with insulin alone, or insulin with 
amino acids. B) Tissue mass of Adiponectin-Cre RagA L/L and corresponding 
controls. (n=6) C) Western blots for indicated proteins of WT and RagA KO mice. 
D) Histology representative of BAT and WAT depots from WT and KO mice. 
(n=6) E) Protein and mRNA levels of Ucp1 F) Insulin tolerance test for WT and 
KO mice on chow diet at 22C housing conditions. (n=6) (Data were analyzed by 
Student’s t-test. Values expressed as mean ±SEM. *p < 0.05; **p < 0.01; ***p < 
0.001). 
 
RagA KO mice are not resistant to HFD induced obesity. 
Adiponectin-Cre Rag A mice were challenged with a 60% kcal high-fat 
diet, under normal (22C) housing temperatures. Adult mice at ~10 weeks of age 
were fed HFD for a total of 8 weeks. Despite higher Ucp1 expression seen in the 
chow diet cohort, HFD fed KO mice gained similar amounts of body weight when 
compared to controls [Figure 4.2A]. Fat mass, brown and white, were again 
similar between KO and control mice, along with lean tissues including liver. 
Again, RagA KO did not appear to produce any type of lipodystrophy similar to 
what was seen in Raptor KO [Figure 4.2B]. RagA deletion did not appear to 
impair mTORC1 signaling in adipose tissue of these mice [Figure 4.2C]. 
Histological analysis also did not reveal major changes in adipocyte morphology 
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or size due to RagA deletion [Figure 4.2D]. Lastly, insulin sensitivity remained 
comparable to control HFD fed mice [Figure 4.2E].  
 
Figure 4.2: RagA KO mice are not resistant to HFD induced obesity. A) Body 
weight gain in response to HFD feeding. (n=6) B) Tissue mass comparison 
between WT and KO mice. (n=6) C) Western plots of indicated proteins from 
iBAT and sWAT of WT and KO mice. D) Representative histology of BAT and 
WAT. E) Insulin tolerance test of animals after 7 weeks of HFD feeding at 22C 
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housing conditions. (n=6) (Data were analyzed by Student’s t-test. Values 
expressed as mean ±SEM. *p < 0.05; **p < 0.01; ***p < 0.001). 
 
Increased UCP1 expression persists at thermoneutrality, but does not alter 
energy balance 
Further environmental factors were selected in an attempt to reduce noise 
and magnify any metabolic effects of RagA that may be present. Adiponectin-Cre 
RagA breeding colonies were housed at thermoneutral temperatures (30°C) in 
order to generate KO mice that develop in an absence of BAT and Ucp1 
stimulating cold stress. Like the previous experiments, RagA appeared to be 
dispensable for overall adipose tissue function. Despite persistent increased 
expression of Ucp1 [Figure 4.3D], KO mice did not have lower body weight or AT 
tissue weights [Figure 4.3A, B]. Morphologically, the BAT of both control and KO 
mice appeared to take on a “white” type appearance, but Ucp1 expression was 
equivalent between the cohorts [Figure 4.3C]. 
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Figure 4.3: Increased UCP1 expression persists at thermoneutrality, but 
does not alter energy balance A-B) Body weight and tissue mass for adult WT 
and KO mice raised at thermoneutrality. (n=6) C) Histology of WAT and BAT for 
WT and KO mice at thermoneutrality. D) mRNA expression of Ucp1 (n=6) (Data 
were analyzed by Student’s t-test. Values expressed as mean ±SEM. *p < 0.05; 
**p < 0.01; ***p < 0.001). 
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Adiponectin-Cre RagA RagB dKO mice do not phenocopy Adiponectin-Cre 
Raptor KO mice. Adipose deletion of RagGTPases is dispensable for 
overall metabolic health in mice. 
To examine the possibility that RagB may be compensating for the loss of 
RagA, and contributing to the maintenance of mTORC1 activity, I generated mice 
that lacked RagA and RagB in mature adipocytes (Adiponectin-Cre RagA L/L 
Rag B L/-). When ablating RagA and RagB specifically in mature adipocytes, I 
find that loss of the amino acid sensing GTPases again does not phenocopy 
Raptor ablation [Figure 4.4A]. Despite efficient deletion in AT depots, I see that 
generally downstream targets of mTORC1 remain active [Figure 4.4B]. Despite 
this, brown adipose tissue in fact expands in mass, with significant lipid 
accumulation [Figure 4.4B, D]. These mice do not suffer from lipodystrophy or 
insulin resistance as would be expected if RagAB dKO were to inhibit mTORC1 
signaling. When challenged with a high fat diet, RagAB dKO mice retain ability to 
expand their AT depots greatly, unlike Raptor KO mice [Figure 4.4C]. RagAB 
dKO animals appear to have slightly smaller sWAT depots, and smaller livers as 
well. This slight, but statistically significant, change in SAT and liver mass does 
not appear to improve insulin sensitivity in these mice [Figure 4.4C]. It is prudent 
to note that the BAT depots of RagAB dKO mice appear to accumulate larger 
lipid both at chow fed and HFD conditions when housed at 22C [Figure 4.4D, E]. 
Also notable is that UCP1 expression increases in the WAT, a phenomenon 
previously associated with Rag GTPase signaling [124] [Figure 4.4B]. This UCP1 
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expression is also increased in a RagA single KO model, where mTORC1 
signaling is not perturbed, suggesting the RagGTPases may play a role in UCP1 
regulation in WAT, though this does not appear to have a whole body metabolic 
effect. 
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Figure 4.4: Adipose tissue RagGTPase deletion does not phenocopy 
Raptor KO mice. Adipocyte RagGTPases appear to be dispensable for 
overall metabolic stability. A) Tissue mass of Control, and Adiponectin-Cre 
RagA/RagB double KO mice. Adult mice at 10 weeks of age on chow diet at 
22°C. B) Western blots from iBAT and sWAT of WT and KO animals for indicated 
proteins. C) Tissue weight and ITT from WT and KO animals at 18 weeks of age 
after 8 weeks of 60% HFD feeding. (n=6) D) Representative H&E staining of 
iBAT and sWAT depots from WT and KO animals on chow diet (n=6) E) 
Representative H&E staining of iBAT and sWAT depots from WT and KO 
animals on HFD. (n=6) (Data were analyzed by Student’s t-test. Values 
expressed as mean ±SEM. *p < 0.05; **p < 0.01; ***p < 0.001). 
 
Discussion: 
In this chapter I demonstrate that the RagGTPases may have a less 
significant role in the regulation of mTORC1 activity in vivo than they appear to 
have in vitro. Initially, I expected adipocyte Rag ablated to phenocopy Raptor KO 
given the current literature indicating that RagGTPase activity is required for 
mTORC1 localization, and downstream activation. While mTORC1 signaling in 
cultured primary adipocytes appeared to be amino acid sensitive, this was not 
recapitulated in various mouse KO models.  
My first mouse model was generated only to delete RagA with the 
understanding that it is the dominant Rag, and that RagB appeared to be 
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dispensable for mTORC1 activity [121]. Initial results were surprising in that 
RagA deletion had no effect on mTORC1 signaling in adipose tissue, and KO 
mice were phenotypically normal, although they did express higher Ucp1 levels 
in sWAT depots. In light of this, I thought it was possible that the increased Ucp1 
expression may have a metabolic effect on these mice if they were put under 
certain conditions such as high-fat diet (to test weight gain), and thermoneutrality 
(to test energy balance absent environmental stress). Putting the RagA mice 
separately on HFD, or at thermoneutrality, however did not reveal any metabolic 
abnormalities or changes in weight gain and adipose tissue accumulation. 
Together these data indicate that, while RagA may be inducing some type of 
Ucp1 expression in WAT, this increase does not alter the energy balance of KO 
mice.  
The second question to understand from the RagA mice is why is 
mTORC1 signaling not perturbed? One possibility is that RagA ablation alone is 
not sufficient to eliminate RagGTPase activity, and that Rag B, of the RagB/D 
complex, is able to compensate and maintain mTORC1 localization. There is 
evidence to support this in that I saw increased RagB protein levels in the RagA 
single KO mice [Figure 4.4C]. To address this possibility, I generated Rag A/B 
dKO mice. The dKO mice did appear to result in a more severe decrease in 
canonical mTORC1 signaling, particularly in the BAT, however they still did not 
phenocopy adipose Raptor KO. These results suggest that the RagGTPases 
may be involved in fully activating mTORC1 in adipocytes, however, mTORC1 is 
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still able to phosphorylate common targets in the absence of Rag activity. 
Interestingly, Ucp1 is persistently elevated in RagAB dKO, supporting the idea 
that Rags alone have an mTORC1 independent role in regulation of Ucp1 
expression in WAT [124].  
 
Conclusion: 
The results from this chapter were generally surprising. First, they support 
the idea that RagGTPases may play in role in an mTORC1-independent pathway 
regulating Ucp1 expression in WAT. This idea is supported in the literature by a 
study examining RagC and D and their involvement in the role of “browning” 
[124]. Specifically, it’s been shown that increased Ucp1 by PGC-1β is regulated 
by RagC/D dependent localization of TFE3. Mechanistically, it has been 
proposed that FLCN interaction with mTORC1 is RagC/D dependent. Lack of this 
interaction leads to activity of TFE3 and PGC-1β to induce a non-canonical 
activation of Ucp1 and “beiging” of WAT. However, I find the increased Ucp1 
expression appears to have little impact on energy balance, even in conditions 
that should be sensitive to increased energy expenditure such as at 
thermoneutrality or on high-fat diet. 
Secondly, my data argue against the model that Rag activity is necessary 
for mTORC1 activation. Significant differences that may be found between in 
vitro and in vivo conditions. While few in vivo studies involving Rag have been 
published, there is some evidence that tissues genetically ablated for Rags may 
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still maintain some level of mTORC1 signaling. Further work will need to be done 
to understand how mTORC1 may be signaling in absence of RagGTPases. Two 
possibilities include: 1 - mTORC1 is still able to respond to amino acids and 
localize to the lysosomal membrane through alternative pathways, or 2 – 
mTORC1 can be activated and phosphorylate its downstream targets in areas of 
the cell other than at the lysosomal membrane. Further thoughts on this are 
discussed in the next chapter.  
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CHAPTER 5: DISCUSSION AND FUTURE DIRECTIONS 
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Adipose mTORC1 
Initially, based on current knowledge in the field, I aimed to study the role 
of mTORC1 signaling in regulating adipocyte metabolism. At the time, significant 
work had been done to elucidate mTORC1 dependent signaling pathways. While 
much of this work was done in vitro, mTORC1 was well understood to be a major 
metabolic node. These studies had involved mTORC1 with many downstream 
anabolic pathways, including protein synthesis, nucleotide synthesis, lipogenesis, 
and autophagy inhibition [28]. Additionally, in vivo work had been done to show 
the importance of mTORC1 signaling in maintaining muscle development and 
mass [125]. Less understood was the role of mTORC1 in mature adipocytes. The 
current model had used the aP2-Cre to delete Raptor, however as discussed 
previously, the aP2-Cre had fallen out of favor in adipose tissue models [62, 89]. 
First, criticisms of the aP2-Cre included evidence that in addition to adipocytes, it 
also targeted the brain, endothelial cells, macrophages, and embryonic tissues. 
These multiple off-target tissues may have significant contributions to the 
phenotype of the mice, especially considering the many known roles of 
mTORC1. To address this, I generated Adiponectin-Cre driven Raptor KO mice 
and found that, surprisingly, these mice had a vastly different metabolic outcome 
than the current model. Contrasting the metabolic efficiency seen in the aP2-Cre 
mice, these mice were metabolically unfit, and suffered from progressive 
lipodystrophy and associated metabolic disease.  
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Adiponectin-Cre Raptor Caveats 
It is important to note that, despite higher specificity and efficacy with the 
Adiponectin-Cre, there remain multiple caveats with my model. While a vast 
improvement over aP2-Cre, Adiponectin-Cre may also have off-target expression 
that contributes to some of the phenotypes observed. Additionally, using a 
constitutive Cre means that expression of the Cre, and thus recombination, will 
occur in this case immediately after differentiation of the adipocyte. This may 
significantly interfere with animal development as mouse adipose tissue depots 
form as early on as in utero [126]. While this may be helpful to study the role of 
adipose mTORC1 in development, it makes it more difficult when trying to 
compare the model to adult-onset metabolic dysfunction. On a related note, 
because of this congenital deletion, I am also only able to see the long-term 
effects of adipocyte Raptor ablation in these mice. Without having the ability to 
control the timing of deletion, I am unable to differentiate acute responses to 
mTORC1 ablation versus chronic, secondary adaptations. Lastly, it was 
mentioned earlier that there was a need to understand the effects of kinase 
inhibitors on normal tissue. Unlike these kinase inhibitors, a Cre driven genetic 
ablation of Raptor will likely not affect translated proteins or already assembled 
mTOR complexes. As a result, mTORC1 inhibition in my model relies on the 
turnover of already made protein, after recombination occurs. This differs from 
the relatively immediate effects on signaling when using kinase inhibitors. 
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 Several of the aforementioned caveats have been or can be addressed, 
while others may prove to be more difficult. On the complications with a 
constitutive, congenitally expressed Cre, I was able to address this by developing 
inducible genetic models again linked to an Adiponectin promoter. In subsequent 
studies, I was able to use these alternative tools to then interfere with mTORC1 
at specific time points of development. This allowed me to bypass any possible 
developmental effects of early mTORC1 inhibition, and also allowed me to study 
acute versus chronic responses to Raptor deletion. Off-target expression of Cre 
promoters is an unfortunate concern for all models. While Adiponectin-Cre 
appears to be a very promising tool to target mature adipocytes, there may be 
more specific and effective promoters yet to be discovered. On the topic of 
kinase inhibitors, unfortunately the genetic models will be limited and dependent 
on protein turnover. In vitro, this can be addressed by studying primary 
adipocytes in culture, and using said inhibitors, however adipocytes in culture are 
not exposed to the complexity of a complete adipose depot. Of interest is the 
development of 3D scaffolds to better mimic adipose tissue structure in culture. 
Some materials used include plasma, alginate, fibrin, and collagen [127]. While 
an improvement over 2D dish surfaces, still lacking is are the complex intra-
organ signaling factors that are constantly in flux in an animal system.  
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Dissecting WAT vs BAT roles in Whole Body Metabolism 
One interesting question to pursue is what is the contribution of white 
adipose tissue dysfunction to the metabolic dysfunction seen in Adiponectin-Cre 
Raptor KO mice? While it’s been discussed that mTORC1 signaling appears to 
be critical for brown fat development, function, and maintenance, these brown fat 
specific KO mice (Ucp1-Cre driven) do not appear to have severe metabolic 
disorders [76]. This suggests that the white adipose tissue may be a main driver 
towards the insulin resistance and liver steatosis seen in adipose Raptor KO 
animals. Furthermore, it is understood that adult humans generally have very 
little brown fat, particularly those who are obese, and those who have access to 
adequate shelter. In fact, it has been suggested that mice housed at 
thermoneutrality, consuming a high-fat diet, most closely mimics a modern 
human metabolic state [128]. For this reason, I believe it would be beneficial to 
further study the role of mTORC1 signaling specifically in white adipose tissue. 
Unfortunately, at this time there are no known Cre promoters that specifically 
target mature white adipocytes, however with growing interest in understanding 
the origins of adipocytes, some may be developed in the near future. 
By developing drug inducible deletion models, I was able to better 
differentiate acute and chronic responses to mTORC1 inhibition in vivo. In vitro, I 
was also able to inhibit Raptor in primary differentiated adipocytes, and saw that 
adipocyte maintenance and lipid accumulation were in tact acutely. Again, these 
genetic models are not perfect, and may be confounded by off-target effects, and 
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delayed downstream signaling inhibition due to existing complexes at time of 
recombination. Additionally, there are concerns that the drugs used for deletion 
have negative effects on adipose tissue themselves. Tamoxifen has been shown 
to have lipotoxic properties, while doxycycline is a mitochondrial toxin that may 
also perturb the microbiome. With this in mind, however, the phenotypes seen in 
inducible mouse models compared very closely with that of constitutive models, 
suggesting minor, if any, deleterious metabolic consequences of the drug 
treatment. With these inducible mice, I was able to show several signaling 
responses occur well before the onset of lipoatrophy and metabolic dysfunction. 
Additionally, cell death and lipoatrophy are dependent on unhinged autophagic 
flux during Raptor ablation, however, adipose tissue inflammation and ectopic 
lipid deposition still occurred even when overall adipose tissue mass was 
recovered by autophagy inhibition.  
 
Further Work for Adipose ATG7/Raptor dKO  
In the immediate future, there are several experiments I believe are 
worthwhile to conduct to further understand the role of autophagy in Raptor KO 
mice. First, I would better characterize the metabolic status of Atg7 Raptor dKO 
animals. Analysis of insulin tolerance tests and glucose tolerance tests are key, 
along with possible utilization of a metabolic cage study, although I would not 
expect to have a difference in energy consumption given that they do not vary 
from control animals with respect to overall body mass. I mentioned that 
 
115 
signaling changes in adipose tissue precede the development of lipoatrophy and 
disease in the Raptor KO mice. One prominent change is an increase in 
expression of de novo lipogenesis proteins, and expression of Chrebp, a gene 
closely linked with glucose uptake. While expression increases, it is not known 
how the actual nutrient flux is affected under these conditions. It may be 
worthwhile to analyze glucose and lipid uptake in adipose tissue of KO mice, 
both in single Raptor KO and Atg7/Raptor double KO. Because this expression 
phenomena persists in the double KO model, it may be a significant contributor 
to overall metabolic dysfunction. 
 Regarding metabolic dysfunction, it is evident that restoring adipose tissue 
mass through inhibition of autophagy is not sufficient to prevent ectopic lipid 
accumulation and adipose tissue inflammation. These results indicate that 
mTORC1 separately regulates autophagy, and other signaling pathways in 
adipose tissue that globally affect metabolism. While adipose tissue mass is 
important for the proper storage of excess nutrients, my results suggest that 
mTORC1 signaling mediates adipose tissue inflammation and whole-body 
metabolism independent of lipid accumulation. Possible mechanisms might 
include mediation of AT inflammation and macrophage recruitment, adipokine 
production, and lipid turnover/release. It would be interesting to examine the 
adipocyte secretome in the setting of Raptor KO. Further metabolomic studies of 
these animals may uncover interesting and novel aspects of whole body 
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metabolic regulation that are dependent specifically on adipocyte mTORC1 
activity.  
In a longer timeframe, I would cross into the double KO animals the 
mTmG reporter. In our Raptor KO mice, the mTmG reporter proved to be a 
valuable tool to track deleted adipocytes, showing that overtime these cells 
shrank in size, and the depot was repopulated with unlabeled cells. Importantly, 
the double KO mice with the mTmG reporter should be driven by inducible Cre 
promoters, as this will give the ability to pulse and trace adipocyte fate in an adult 
mouse. Issues would arise if using a constitutive Adiponectin-Cre both due to 
developmental concerns, and an inability to differentiate between new and old 
cells. While blocking autophagy does not appear to block adipose tissue 
inflammation, it would be interesting to see if in fact elevated autophagic flux was 
the sole cause for the apparent shrinkage of these KO adipocytes. Further, I’ve 
mentioned the relevance of thermoneutrality conditions to normal human life. It 
can be argued that any study attempting to use mice to model human 
metabolism should be conducted at the very least under thermoneutral 
conditions, if not also paired with high-fat diet feeding. It is apparent that 
perturbed mTORC1 signaling in adipocytes may contribute to metabolic 
dysfunction, even when adipose tissue mass is maintained. To best emulate and 
compare these findings with human metabolic disease, I believe there will be a 
benefit to studying these mice under humanized conditions.  
 
 
117 
Can Adipocyte mTORC1 Localize to Lysosomes Absent RagGTPases? 
On the topic of amino acids, my in vivo findings greatly contrast the well-
established model of the amino acid sensing complex in cancer cells. Strong 
evidence indicates that mTORC1 localization to the lysosomal membrane, by the 
amino acid sensing RagGTPase complex, is a required step in the process of 
mTORC1 activation. While I confirm that adipocytes are amino acid sensitive in 
culture, I also find that the RagGTPases may be dispensable for adipose tissue 
in vivo. At this point, I believe it is imperative to see if mTORC1 is in fact able to 
localize to the lysosome in absence of the RagGTPases. This would most easily 
be conducted in culture, and could be carried out using primary adipocytes 
isolated from RagA/B dKO mice. Similar to the model used for the Raptor model, 
I would develop a drug-inducible system to genetically delete the RagGTPases in 
primary isolated cells. Alternatively one could use CRISPR to efficiently delete 
the RagGTPases in an adipocyte cell line, as this may be faster than generating 
the mice needed for primary cells. The caveat again being that in vitro studies 
poorly mimic in vivo conditions, and that often many differences arise between 
the two models, especially if desired readouts are dependent on nutrient flux and 
microenvironmental conditions. In vivo tracking of mTORC1 localization would be 
ideal. One approach could be the use of fluorescence electron microscopy. By 
fluorescently labeling a component of mTORC1, fluorescence electron 
microscopy may provide high enough resolution to show if mTORC1 is 
colocalizing with lysosomes in the setting of RagGTPase deletion. Lastly, it 
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should be noted that there was a persistent increase in Ucp1 expression in the 
WAT of Rag KO animals. While this did not appear to have any gross metabolic 
effect, it may still be an interesting phenomenon to study further. It has been 
reported before that RagC/D may be linked to Ucp1 expression [124]. More 
specifically, it is reported that RagC/D dependent activity of mTORC1 regulates a 
noncanonical TFE3-PGC1β-UCP1 pathway, which is responsible for mTORC1 
dependent suppression of UCP1 activity by FLCN. Interestingly, it was shown 
that RagD activity could regulated TFE3 sequestration but not RagB activity. This 
model suggests a role of the Rags in Ucp1 activity, however does not necessarily 
explain the phenomenon I see in that both RagA, and RagA/B deletion promote 
Ucp1 expression in WAT. It is possible that the presence of RagA or B is 
required for stability of C/D, and that the TFE3 axis may still be responsible for 
the increased Ucp1 that I find in my animal models. For curiosity’s sake, it would 
be interesting to further understand the Rag specific control of Ucp1 expression 
in WAT, even though it may not be of any major metabolic consequence. 
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Figure 5.1: Diagram of known carriers for amino acid sensing. Speculative 
pathways highlighted in red.   
 
Adipocyte Mitochondrial Dynamics in Relationship With mTORC1 
In my study of Raptor KO adipocytes, I saw a significant change in overall 
mitochondrial mass, and morphology. mTORC1 has been associated with both 
mitochondrial dynamics, and biogenesis, through various mechanisms. While my 
studies were limited to observing the general morphology, it may be worthwhile 
to better understand the functional capacity of these “mutant” mitochondria. 
While they undoubtedly grow massively in size, is it possible that they are less 
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efficient metabolically than normal mitochondria? In the setting of over active 
autophagy, or blocked autophagy, do these mitochondria accumulate excessive 
damage? I would start with studying the respiratory capacity of Raptor KO cells 
by utilizing the Seahorse metabolic analyzer. I would also utilize mitochondrial 
damage and stress kits to analyze mitochondrial health in these cells. Overall, 
the relationships that have been made between mTORC1 and mitochondrial 
dynamics are intriguing, and my findings add to the current evidence that 
mTORC1 is critical in mitochondrial maintenance. Further work to understand the 
importance of mitochondria in adipocytes is warranted.  
 
mTORC1, Adipose Tissue Health, and Tumor Environments 
From my work, I have developed a particular interest in the association 
between obesity and cancer. Obesity has been clearly linked with increased risk 
of developing several types of cancer, including breast, colon, endometrial, 
esophageal, kidney, and pancreatic cancers [129]. Many theories have been 
proposed to link obesity with these cancers, including altered immune function, 
inflammation, elevated growth factor circulation, epigenetic modifications, and 
more [130-132]. In particular, women who are obese have been shown to have a 
20%-40% high risk of developing breast cancer, and a 5-point increase in BMI 
has been associated with a 12% increase of developing breast cancer [133]. This 
is highly interesting to me given the localization of breast cancer, as it develops 
within an adipose tissue environment. One theory suggests that simply the 
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excessive nutrient availability of large adipose stores “feed” local cancer cells 
leading to tumor growth [134]. While possible, I wonder if it may be more 
complicated, and that perhaps the “health” of surrounding adipose tissue may be 
important in tumor development. If health, more than gross mass, is important, I 
believe that tumor growth may be promoted in a lipodystrophic model as much as 
it would in an obese model. If inflammation is a contributory factor, it is possible 
that adipose tissue inflammation, seen both in obese and in lipodystrophic 
settings, is providing a tumorigenic environment within the breast tissue. To study 
this, I would utilize the Adiponectin-Cre Raptor model of lipodystrophy and 
xenograft a breast tumor line within the mammary adipose tissue depot. Initially, 
tumor development can be compared between control, KO, and possibly control 
mice on high-fat diet to mimic obesity. It would be prudent to conduct these 
experiments under humanized conditions as well. If particularly ambitious, one 
could also utilize the Atg7/Raptor double KO mice as they also suffer from 
inflammation, despite preserving adipose tissue mass. I believe the Raptor KO 
model can be an extremely useful tool in studying the development of cancer 
within the setting of adipose tissue dysfunction. While straying away from the 
original goals of this project, it would be an interesting avenue to connect adipose 
tissue function with development of related serious diseases. 
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Conclusion: 
The results of this dissertation have provided novel insight into the role of 
mTORC1 and nutrient signaling in regulating mature adipocyte function. I have 
argued against the model that adipocyte mTORC1 loss may be metabolically 
beneficial, and have shown that mTORC1 is in fact critical in adipose tissue 
growth and maintenance. In animal models, loss of mTORC1 signaling in mature 
adipocytes leads to a progressive loss of adipose tissue mass, and development 
of severe metabolic dysfunction including insulin resistance, hepatosteatosis, and 
hepatic tumors. I also show that, while mTORC1 dependent inhibition of 
autophagy is critical for adipose tissue mass, restoring mass alone is not 
sufficient to prevent whole body metabolic disturbances such as adipose tissue 
inflammation, and ectopic lipid accumulation in the liver. These findings suggest 
that metabolic homeostasis is dependent not only on the ability of adipose tissue 
to store lipids, but also on how the adipocytes function internally, with respect to 
nutrient and growth factor signaling. mTORC1 appears to regulate important 
adipocyte signaling pathways that have a global effect on metabolism. While 
some questions are answered, many more now arise. Continued work in 
understanding metabolic signaling in adipose tissue will undoubtedly lead to 
beneficial discoveries in human health and disease.  
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Figure 5.2: Model of mTORC1 pathways and their influence on adipose tissue 
metabolism in wildtype (A), adipose Raptor KO (B), and adipose ATG7/Raptor 
KO (C) mice. 
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